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Abstract 
In pre-cancerous lesions the overexpression of oncogenes such as Myc not only drives 
aberrant cellular proliferation, but also triggers a strong DNA damage response (DDR) that 
is in part due to DNA damage accumulating at the level of stalled replication forks. This 
oncogene-induced DDR is an effective barrier to cancer development and represents a 
relevant tumor suppressive mechanism. Conversely, at later stages of malignancy DDR 
signaling may function in favor of cancer progression. Such tumor promoting role of DDR 
may be needed for cancer cells to avoid accumulation of cytotoxic DNA damage under high 
level of oncogene-induced replication stress. Recently it has been shown that targeting 
regulators of replication checkpoint such as ATR or Chk1 in Myc-overexpressing cells 
caused apoptosis and prevented tumor formation, suggesting a crucial role for this pathway 
in ensuring cancer cell viability and offering the chance of developing new targeted 
therapies against cancer cells.  
In an effort to identify the modulators of Myc-induced replicative stress, we carried out a 
high-throughput RNAi screen based on immunofluorescence detection of ϒH2AX, a DNA 
damage marker. Quantification of the number of cells and the percentage of ϒH2AX-
positive cells, identified hits that exhibited differential cell viability (synthetic lethal hits) 
and/or enhanced ϒH2AX signal (DDR-up hits) in Myc-overexpressing cells compared to 
normal cells. Validated hits encompass a variety of pathways and biological processes and 
have different molecular functions. As a proof of principal, we selected SRSF3 and Cdk12 
and confirmed the synergistic effect of Myc overexpression and depletion of SRSF3 or 
Cdk12 on accumulation of cytotoxic DNA damage response as marked by H2AX 
phosphorylation.  
For further mechanistic investigations, we selected Rad21, a component of the cohesin 
complex, which was also reported as a Myc-synthetic lethal candidate previously. Using 
 
 
 viii 
small inhibitory RNAs against Rad21, we confirmed that depletion of Rad21, increased 
ϒH2AX level and subsequently led to cell death, selectively in Myc-overexpressing cells. 
We provide evidence that while Rad21 is necessary for proper and efficient DNA synthesis, 
replication reinforcement imposed by Myc overexpression in Rad21-depleted cells results in 
replicative stress. In addition, we observed that Myc, as a transcription factor, could 
partially rescue transcriptional alterations due to Rad21 depletion. The conflicts between 
DNA replication and transcription in Rad21-depleted cells upon Myc activation may be the 
source of increased R-loops detected in these cells. 
In summary, by means of a genetic loss of function screen we identified several candidates 
that may be involved in protecting Myc-overexpressing cells against ample replicative 
stress, thus revealing targets for potential therapeutic intervention in Myc-driven cancers.  
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1 Introduction 
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1.1 DNA Damage Response (DDR) 
1.1.1 DDR signaling 
1.1.1.1 The importance of DNA damage response 
The genome in each cell is under constant attack by agents that can damage its DNA. 
These threats against DNA integrity can originate from exogenous sources such as 
ultraviolet (UV), ionizing radiation (IR) or DNA-damaging chemicals in contaminated 
foods. In addition, DNA damage may also arise endogenously, for example, as a result of 
defects in DNA replication or by chemical modifications due to reactive chemical 
intermediates like free oxygen radicals generated during oxidative respiration (Sancar et 
al., 2004). These lesions should be resolved before mitosis takes place in order to avoid 
that the damaged DNA is passed to daughter cells. To combat these assaults, cells have 
evolved a series of mechanisms termed DNA-damage response (DDR) to sense the DNA 
lesions, signal their presence and activate repair mechanisms and other effector pathways 
(Zhou and Elledge, 2000). As a consequence of the activation of the DDR signaling, cells 
can cope with DNA damage by transient or permanent arrest in cell cycle progression or 
by undergoing programmed cell death.  
In the next part, the molecular mechanisms of the cellular response to DNA damage is 
briefly reviewed followed by discussions on its role in cancer. 
1.1.1.2 How DDR is regulated 
As mentioned above, DNA can be damaged in a variety of ways by either 
exogenous or endogenous agents. Reactive oxygen species (ROS) -generated as the by-
products of oxidative respiration- and ionizing radiation can break the phosphodiester 
bonds in the backbone of the DNA helix. When the two single strand breaks in the 
opposite DNA strands are close together, this may result in a double-strand break (DSB), 
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a vicious form of DNA damage which poses a severe threat for the integrity of the 
genome (Kastan and Bartek, 2004). Alkylating/intercalating agents can cause intra-strand 
or inter-strand crosslinks that should be resolved before DNA replication begins. 
Inhibitors of DNA topoisomerases can lead to single or DSBs depending on the type of 
enzyme inhibited and the cell cycle phase (Froelich-Ammon and Osheroff, 1995). 
Inducing oncogenes, as will be discussed later, at least partly by boosting S-phase entry 
and DNA synthesis may cause replication stress (Macheret and Halazonetis, 2015). Under 
such conditions, if DNA polymerases stall, MCM replicative helicases continue 
unwinding DNA ahead of the replication fork, leading to the generation of single strand 
breaks. Then, if the replication process fails to restart, replisome components dissociate 
and the replication fork can collapse, leading to the formation of DSBs (Zeman and 
Cimprich, 2014). Therefore, despite the variety of potential DNA lesions, their processing 
often leads to the generation of single or double strand breaks that serve as the signals for 
initiating the DDR signaling pathway. Depending on the type of the DNA damage, the 
DDR pathway relies on the activation of different members of the PI3K-like kinases 
family (PIKKs): ATM (ataxia telangiectasia mutated), ATR (ataxia-telangiectasia and 
Rad3-related) and DNA-PKcs (DNA-dependent protein kinase catalytic subunit) (Harper 
and Elledge, 2007).  
Although protein kinases ATM and ATR belong to a same PIKK family with a common 
target motif (Ser/Thr-Gln-Glu), gene disruption studies have shown little genetic 
redundancy of these proteins. For example, cells derived from ataxia-telangiectasia (A-T) 
patients (with heterozygous ATM mutation) as well as atm
-/-
 mice display 
hypersensitivity to ionizing radiation and defects in DNA damage checkpoints. However, 
these cells are not sensitive to ultraviolet or replication inhibitors (Klose et al., 2006, 
McKinnon, 1987, Barlow et al., 1996, Canman et al., 1998, Painter and Young, 1980). On 
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the other side, ATR is an essential gene and hypomorphic mutant of ATR, unlike ATM-
deficient cells, is sensitive to UV and inhibitors of DNA replication (Brown and 
Baltimore, 2000, Cliby et al., 1998, Wright et al., 1998, de Klein et al., 2000). For these 
reasons, it is commonly believed that ATM is mainly responsible for detecting and 
signaling the presence of DSBs, whereas ATR is engaged in the cellular processes that 
affect the progression of replication fork such as DNA damage generated by replication 
fork stalling and UV radiation. Single protein analyses as well as various screens for 
finding the ATM and ATR substrates identified over 700 proteins that become 
phosphorylated in response to IR or UV (Matsuoka et al., 2007, Stokes et al., 2007). One 
of the most enriched categories in these studies was the DNA replication module 
including MCMs, ORC (origin recognition complex) and DNA polymerases, arguing the 
impact of DDR on DNA replication and G1/S checkpoint. The other top enriched module 
was DNA repair. Several factors known to have a role in various DNA repair processes -
such as excision repair, mismatch repair, crosslink repair, homologous recombination 
(HR) and transcription-coupled repair were classified in this group which could explain 
the cooperation between DDR pathway and repair mechanisms to maintain genome 
stability. Besides these two most enriched groups, there were a large number of modules 
whose connection to DDR have not yet been well elucidated. These include pathways like 
RNA splicing, nonsense mediated decay, the spindle checkpoints, chromatin remodeling 
and a number of transcription factors. Prospective studies can further clarify the link 
between DDR and these modules.  
Although the downstream effectors of the other DDR-protein kinase, DNA-PK, are still 
largely unknown, it seems that this kinase is a DSB sensor required for non-homologous 
end-joining (NHEJ). Upon generation of a DSB, this protein is recruited to the site of the 
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damage via the Ku70-Ku80 heterodimer and by its catalytic subunit -that has DNA-end 
binding activity- promotes rejoining of the DSB (Durocher and Jackson, 2001). 
1.1.1.3 DNA damage signal initiation 
In response to DSBs, a complex called MRN, consisting of Mre11-Rad50-Nbs1, senses 
the damage and along with chromatin structural changes around DSBs, such as histone 
acetylations, favor the recruitment of ATM to the broken DNA (Price and D’Andrea, 
2013, Uziel et al., 2003, Sulli et al., 2012). ATM exists as an inactive dimer but once 
recruited to a DSB, the dimer dissociates and this conformational change exposes certain 
residue (serine 1981) to ATM autophosphorylation that is crucial for maintaining ATM 
activation (Bakkenist and Kastan, 2003). Once activated, ATM orchestrates a signaling 
cascade based on its kinase activity. Among the ATM substrate there is also the MRN 
complex whose phosphorylation is important for recruiting other substrates like BRCA1 
and SMC1 (structural maintenance of chromosomes 1) to ATM, thus the MRN complex 
serves also as an amplifier of the ATM-dependent DNA damage signaling. ATM can also 
phosphorylate other nucleoplasmic substrates such as p53 (Shiloh and Ziv, 2013).  
Unlike ATM, whose activity is minimal in unstressed cells but is stimulated in the 
presence of damage, in vitro kinase assay indicated that ATR kinase activity remains 
constant after treatment with genotoxic agents, suggesting that ATR activity may be 
regulated by subcellular localization (Abraham, 2001). ATR exists in a complex with the 
ATR-interacting protein (ATRIP) and localizes with single-strand DNA (ssDNA) by 
means of ATRIP interaction to RPA, that is present on abnormal stretch of ssDNA. In this 
way, single strand DNA decorated by the RPA complex is the initial signal that plays two 
main roles: it recruits the ATR protein through its regulatory subunit ATRIP and it 
recruits RAD17 clamp loader. RAD17 clamp loader then becomes phosphorylated and 
activated by ATR to recruit PCNA-related 911 complex (RAD9-RAD1-HUS1) to 
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ssDNA. ATR can also phosphorylates TopBP1 which binds 9-1-1 complex and was 
shown to stimulate ATR kinase activity through interaction with ATRIP (Harper and 
Elledge, 2007, Zou and Elledge, 2003, Cortez et al., 2001).  
1.1.1.4 DDR mediators 
Mediators are the modulators of ATM and ATR that act as recruiters of additional 
substrates as well as scaffolds to assemble complexes. The ATM-mediated mediators 
include MDC1 (mediator of DNA damage checkpoint 1), 53BP1 (p53 binding protein 1) 
and BRCA1 (Harper and Elledge, 2007, Stewart et al., 2003). The accumulation of 
mediators into the DNA damage foci depends on ATM-dependent phosphorylation of 
histone H2AX on ser139 (termed ϒH2AX). In such a case the mediators serve as the 
bridges between ϒH2AX and the MRN complex to facilitate ATM signaling (Stucki and 
Jackson, 2006). Similarly, Claspin functions as a mediator in ATR signaling and is 
required for ATR-mediated phosphorylation of the downstream targets (Shechter et al., 
2004).  
1.1.1.5 Effector kinases Chk1 and Chk2 
The most important ATM and ATR substrates are the checkpoint-transducer 
serine/threonine kinases Chk2 and Chk1. As mentioned earlier, regardless of the limited 
cross-talks between the two pathways, ATM preferentially phosphorylates Chk2 whereas 
ATR activates Chk1. In this fashion, the DNA damage signal sensed by ATM and ATR at 
the site of the damaged DNA is conveyed to mobile messenger kinases Chk1 and Chk2 to 
activate the subsequent responses in cells (Figure 1.1) (Reinhardt and Yaffe, 2009). 
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Figure 1.1. The DNA damage response signaling pathway 
The DDR pathway is composed of two main DNA damage sensors the MRN 
complex and the RPA/RAD9-RAD1-HUS1 complexes that detect DSB and 
ssDNA respectively. These sensors then recruit PIKK kinases ATM and ATR to 
the site of DNA damage. Upon activation, ATM and ATR conduct a signaling 
pathway that relies mainly on the phosphorylation of the DNA damage mediators 
and subsequently the downstream kinases Chk2 and Chk1. The outcome of the 
DDR is determined by the activity of the DDR effectors that are activated by 
Chk2 and Chk1 kinases. Adapted from “Crosstalk between chromatin state and 
DNA damage response in cellular senescence and cancer” by G. Sulli, R. Di 
Micco R and F d’Adda di Fagagna, 2012, Nature Reviews Cancer, 12, p. 710.  
1.1.2 The outcome of DDR signaling: checkpoint activation  
A quick outcome of the DNA damage response induction is to halt cell cycle progression 
until the lesions are resolved. In eukaryotic cells control of cell growth and division 
involves molecular circuits known as “checkpoints” that ensure that the earlier process 
such as DNA replication or mitosis have been properly completed (Elledge, 1996). DNA 
damage response can lead to cell cycle blockage through activation of these checkpoints, 
a process called activation of the DNA damage checkpoint. These checkpoints act mainly 
on cell cycle regulators like cyclin-dependent kinases (CDKs) and CdK inhibitors in order 
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to delay cell cycle progression. Alongside the cell cycle arrest, the checkpoint kinases can 
also trigger cellular responses such as DNA repair, apoptosis and cellular senescence 
(d'Adda di Fagagna, 2008, Niida and Nakanishi, 2006, Sancar et al., 2004). 
The G1 checkpoint response which results in G1 arrest in face of DNA damage, is mostly 
dependent on the p53-MDM2-p21 pathway stimulated by ATM/Chk2 or ATR/Chk1. 
ATM and ATR directly phosphorylate the p53 transcription factor particularly on serine 
15 residue, located within the amino-terminal transactivation domain (Banin et al., 1998, 
Hirao et al., 2000, Shiloh, 2003, Tibbetts et al., 1999, Wahl and Carr, 2001). Also the 
ubiquitin ligase MDM2 that normally binds p53 and targets it to ubiquitin-mediated 
degradation is phosphorylated by ATM and ATR, leading to down-regulation of MDM2 
function and p53 stabilization (Maya et al., 2001, Shinozaki et al., 2003). All these events 
contribute to the accumulation of p53 and the enhancement of its transcriptional activity. 
One of the important transcriptional targets of p53 is the inhibitor of cyclin-dependent 
kinase p21, which by inhibiting Cyclin E/Cdk2 blocks G1/S transition. As a result of 
inhibition of Cyclin E/Cdk2 kinase activity, E2F is preserved in the repressed 
transcriptional form bound to RB and thus is unable to activate the expression of the 
subset of genes required for S-phase entry and progression (Bartek et al., 1997, Bates and 
Vousden, 1996, Bartek and Lukas, 2001).  
In the late G1 and early S-phase in response to DNA damage, Cdc25A -a phosphatase 
that removes inhibitory phosphate from Cyclin E/Cdk2 and Cyclin B/Cdk1 complex to 
promote progression into S-phase and mitosis respectively- becomes phosphorylated by 
Chk1. This phosphorylation creates a phosphodegron motif in the protein and 
subsequently leads to Cdc25A ubiquitination by the SCF
ß-TRCP
 ubiquitin ligase and its 
rapid degradation. Following the decrease of Cdc25A, the Cyclin E (A)/Cdk2 complex is 
inhibited and the loading of Cdc45 -an essential replication factor- on replication origins 
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is prevented, causing a delay in S-phase progression (Bartek et al., 2004, Donzelli and 
Draetta, 2003). In addition, phosphorylation of Cdt1 -an important licensing factor for 
DNA replication- during S-phase induces the ubiquitin-mediated destruction of 
chromatin-loaded Cdt1 and leads to the disassembly of the pre-recombination complex 
and a blockage of origins firing and DNA replication (Kondo et al., 2004, Arias and 
Walter, 2007).  
The G2 checkpoint (also known as the G2/M checkpoint) is activated in the case of 
persistent un-resolved DNA lesions occurred in the S-phase or when cells face DNA 
damage during G2, and has the function of preventing damaged cells from initiating 
mitosis (Nyberg et al., 2002, Xu et al., 2002). The key target of G2 checkpoint is the 
mitosis-promoting activity of the Cyclin B/Cdk1 kinase. Likewise G1/S checkpoint, 
down-regulation of Cdc25A in response to DNA damage signaling is an important event 
in the regulation of the G2 checkpoint response (Donzelli and Draetta, 2003, Mailand et 
al., 2002). Furthermore, Plk1 (which promotes ubiquitin-mediated proteolysis of Wee1 
through creation a phosphodegron motif in the protein in normal G2/M transition) is 
inhibited in an ATM/ATR dependent manner and this leads to stabilization of Wee1 and 
inhibition of CDKs in the face of DNA damage (Harper and Elledge, 2007, Smits et al., 
2000). Plk1 in normal cells phosphorylates and thus targets Claspin, an ATR coactivator, 
to SCF
ß-TRCP
-mediated degradation, thus leading to reduced Chk1 signaling and 
preventing cell-cycle arrest (Gewurz and Harper, 2006). Noteworthy, the sustained G2 
arrest may also partly rely on the transcriptional activity of p53, leading to the up-
regulation of cell cycle inhibitors such as p21 and Gadd45a (growth arrest and DNA 
damage inducible 45 alpha) (Bunz et al., 1998, Taylor and Stark, 2001). DDR signaling 
cascade is schematically represented in figure 1.2. 
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Figure 1.2. DNA damage response signaling cascade and its physiological 
consequences 
A schematic representation of the various DDR pathways discussed in the text. 
Adapted from “The DNA Damage Response: Ten Years After” by J. W. Harper 
and S. J. Elledge, 2007, Molecular Cell, 28, p. 740.  
1.1.3 The impact of DDR on cancer 
Genome instability is a hallmark of almost all human cancers. Most carcinogens act by 
generating DNA damage. In addition, individuals with inherited DDR defects are 
commonly prone to develop tumors (Kastan and Bartek, 2004). Aberrant cellular 
proliferation -caused by activation of oncogenes- also has been shown to contribute to 
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genome instability by inducing DNA replication stress and ongoing DNA damage 
formation (Macheret and Halazonetis, 2015, Halazonetis et al., 2008). Therefore, the 
cellular responses to DNA damage in the frame of checkpoints activation and repair 
pathways play a crucial role in maintaining genome stability, while breach in these 
pathways increase the risk of cancer development. Indeed, not only mutations in DNA 
repair genes lead to cancer predisposition, but so do certain mutations in the components 
of DDR signaling pathway and DNA damage checkpoints. For example, loss of ATM or 
inactivating mutations in NBS1 or MRE11 predisposes individuals to lymphoma and 
leukemia development (Shiloh and Kastan, 2001, Stewart et al., 1999, Varon et al., 1998). 
In the case of ATR, hypomorphic mutant mice displayed enhanced tumorigenesis, 
presumably because of the defective DNA-mismatch repair (Fang et al., 2004). Also 
H2AX
Δ/Δ
p53
−/−
 mice (Bassing et al., 2003, Celeste et al., 2003) or mice lacking 53BP1 
(Ward et al., 2003) showed checkpoint defects and cancer predisposition. The inherited 
mutations in one allele of Chk2 are also found in individuals with extremely cancer-prone 
Li-Fraumeni syndrome (Bell et al., 1999). The inheritance of a single mutated allele of 
either BRCA1 or BRCA2 also increases the incidence of breast and ovarian cancer, 
possibly by the loss of heterozygosity of the second allele (King et al., 2003).  
1.1.3.1 Oncogene-induced DDR model 
Overexpression of several oncogenes has been shown to associate with DDR activation 
and cancer development (Halazonetis et al., 2008). The first evidences from the analysis 
of precancerous lesions of various origins, demonstrated that the DNA double strand 
break checkpoint pathway is indeed frequently activated in pre-invasive tissues 
(Gorgoulis et al., 2005, Bartkova et al., 2005). For example, precancerous lesions of lung 
showed enhancement in several markers of DNA DSBs such as phosphorylated histone 
H2AX and 53BP1 foci, phospho-Chk2 and accumulated p53. In addition, these pre-
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cancerous lesions showed sign of apoptosis. However, progression to carcinoma was 
associated with p53 or 53BP1 inactivation and decreased apoptosis (Gorgoulis et al., 
2005). Further studies on different pre-invasive lesions (like hyperplastic lung tissues, 
dysplastic nevi, superficial bladder lesions and colorectal adenomas) demonstrated that 
the activation of DNA damage checkpoints occurs frequently at pre-cancerous stages and 
is associated with cell cycle arrest or apoptosis (Bartkova et al., 2005, Bartkova et al., 
2006, Gorgoulis et al., 2005, Di Micco et al., 2006).  
More investigations on the cause of DNA damage and the subsequent DDR response in 
pre-cancerous lesions, indicated that these lesions have high level of activated oncogenes 
rather than telomeres erosion or mutation in genes responsible for genomic instability 
(Halazonetis et al., 2008, Bartkova et al., 2005, Bartkova et al., 2006). In line with these 
observations, overexpression of oncogenes, such as Cyclin E, Cdc25a and E2F1, in 
cultured cell lines mimicked the characteristic of pre-cancerous lesions regarding the 
activated DNA damage response (Bartkova et al., 2005). Besides activation of ATM-
Chk2 pathway, several targets of the ATR pathway, like Chk1 and Rad17, were also 
found to be phosphorylated in the cells overexpressing various oncogenes (Bartkova et 
al., 2005), linking the oncogene-induced DDR to replicative stress. As the overexpression 
of these oncogenes promotes S-phase entry, it was proposed that the DNA damage 
response might be a consequence of unscheduled DNA synthesis in oncogene-
overexpressing cells. Supporting this idea, U2OS cells overexpressing Cyclin E displayed 
longer replication tracks in DNA combing and increased amounts of hyperphosphorylated 
form of single strand DNA binding replication protein A (RPA) (Bartkova et al., 2006). 
Based on these evidences, oncogene-induced DNA damage model was proposed for 
cancer development and progression. Based on this model, activation of an oncogene in 
precancerous tissues causes aberrant proliferation and may lead to replication stress (RS) 
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defined as inefficient DNA replication due to replication fork stalling and/or collapse 
(Gaillard et al., 2015, Halazonetis et al., 2008, Macheret and Halazonetis, 2015, Bartkova 
et al., 2005). The discovery that fragile sites (difficult-to-replicate genomic sites) showed 
higher likelihood of loss of heterozygosity than other sites of the genome in precancerous 
lesions (Gorgoulis et al., 2005, Tsantoulis et al., 2008) further supported the hypothesis 
that oncogene-induced RS may arise early during cancer development. Activation of the 
DNA damage response pathway in pre-cancerous lesions leads to the activation of a 
tumor suppressive barrier imposed by the DNA damage checkpoints controlled by the 
ATM/Chk2 pathway leading to a proliferative arrest and/or apoptosis, largely mediated 
by p53 activation. Additional mutations in genes involved in the DNA damage response 
(DDR) –such as ATM or p53 inactivation mutations- will breach this barrier thus 
favoring genomic instability and cancer progression (Halazonetis et al., 2008, Macheret 
and Halazonetis, 2015). 
Noteworthy, although many of the DNA damage response factors act as tumor suppressor 
genes in early stage of cancer development, more recently it was proposed that in later 
stage of malignancy, DDR may function in favor of cancer progression (Bao et al., 2006, 
Santos et al., 2014). Such tumor promoting role of DDR may be needed for cancer cells 
to avoid accumulation of ample cytotoxic DNA damage under high level of oncogen-
induced replication stress. The elevated resistance to DNA-damaging chemotherapies 
observed in highly malignant tumors could be at least in part related to this phenomenon 
(Bao et al., 2006). Therefore, it has been proposed that DDR inhibitors might increase the 
efficacy of radio- and chemo-therapy. Chk1 inhibitors were among the first DDR 
inhibitors examined by the pioneer studies on this topic. For example, it has been shown 
that Chk1 inhibition sensitizes p53-deficient tumor cells (but not normal cells) to different 
DNA-damaging agents (Chen et al., 2006, Vitale et al., 2007). These observations also 
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raised the concept of synthetic lethality to target cancer cells with the intrinsic property of 
having high levels of oncogene-induced replicative stress. In agreement with this notion, 
ATR and Chk1 inhibitors -by inducing massive S-phase DNA damage- are particularly 
toxic for cells overexpressing oncogenes such as Cyclin E, Ras and c-Myc (Gilad et al., 
2010, Murga et al., 2011, Toledo et al., 2011). 
1.2 Myc oncogene  
1.2.1 An introduction on Myc protein 
Myc is a master transcriptional regulator whose target genes are involved in cell cycle 
progression, cell growth, differentiation, metabolism and apoptosis (Meyer and Penn, 
2008). Myc protein belongs to the basic Helix-Loop-Helix Leucine Zipper (bHLHZip) 
transcription factor family. The bHLHZip domain in C-terminal domain (CTD) of the 
Myc protein is responsible for site-specific DNA binding and its heterodimerization with 
its protein partner Max. Besides CTD, Myc family members also show high homology in 
regions at the N-terminal domain (NTD) called Myc Box regions (MB1 and MB2) that 
are uniquely present in Myc family members and are required for Myc transcriptional 
activity (Oster et al., 2002). The Myc-MAX complex can activate gene transcription by 
several mechanisms. Myc, through interaction with TRRAP, recruits histone 
acetyltransferase (HAT) complexes to the chromatin to activate transcription of different 
target genes (McMahon et al., 2000). Myc can also regulate gene transcription through 
interaction with IN1/hSNF5 (a component of the SWI/SNF chromatin remodeler 
complex) which modifies chromatin in an ATP-dependent manner (Cheng et al., 1999). 
Accumulating evidence showed that Myc is also involved in RNA polymerase II 
elongation through interaction with components of the RNA polymerasee II CTD kinase 
P-TEFb like Cdk9 and Cyclin T1 (Eberhardy and Farnham, 2002).  
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Myc can also function as a transcriptional repressor of many genes, the best characterized 
are genes involved in cell cycle arrest and adhesion (Kleine-Kohlbrecher et al., 2006), 
however the mechanism of gene repression by Myc is less understood than the 
mechanism of transcription activation. The presence of Myc-MAX complex at the 
promoter of repressed target genes suggests that Myc acts directly in the down-regulation 
of these genes (Kretzner et al., 1992). Indeed it has been shown that Myc interacts with 
transcriptional activators bound to initiator elements (Ir) or transcriptional enhancers such 
as YY1, Miz-1 and NF-Y, thus by tethering and inhibiting the activity of these 
transcription factors represses the transcription of the target genes (Kleine-Kohlbrecher et 
al., 2006). Myc was also shown to contribute to transcriptional repression by promoting 
chromatin modifications (such as histone deacetylation) through recruiting DNA 
methyltransferase Dnmt3a and histone deacetyltransferase to Miz1-bound sites (Brenner 
et al., 2005, Kurland and Tansey, 2008). Noteworthy, by regulating the expression of 
microRNAs, Myc is also able to indirectly repress the expression of the target genes 
(Chang et al., 2008). 
Given the significant role of Myc in gene regulation, it is estimated that this protein is 
bound to   25,000 sites in human genome including RNA pol III- and pol I-dependent 
genes as well as non coding RNAs (Adhikary and Eilers, 2005). This global 
transcriptional regulatory role of Myc reveals its pleiotropic role in virtually every aspect 
of cell behavior (Figure 1.3).  
1.2.2 The role of Myc in cellular processes 
1.2.2.1 Cellular growth  
Myc directly binds virtually all genes involved in glycolysis and glutaminolysis including 
glucose and glutamine transporters as well as glutaminase, and thus potentiates cell 
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metabolism and protein synthesis (Dang, 2013, Wise et al., 2008). Imported glucose can 
participate in glycolysis pathway to produce pyruvate. Pyruvate can be further oxidized in 
the mitochondrion to be converted to acetyl-CoA, which can then participates in the 
elongation of the growing fatty acid chain. Moreover, the glycolytic intermediate 3-
phosphoglycerate is a substrate for lipid biosynthesis as well as precursor for serine and 
glycine. Glucose can also enter into pentose phosphate pathway for the production of 
NADPH and ribose. Glutamine can be transported into the mitochondrion where it is 
converted to glutamate by glutaminase. Both pyruvate and glutamate can then enter 
tricarboxylic acid (TCA) cycle to generate ATP or provide the carbon skeleton for the de 
novo synthesis of pyrimidines and purines (Dang, 2013, Wise et al., 2008). In addition, 
Myc stimulates lipid biosynthesis through regulation of many enzymes in this pathway 
such as acetyl-CoA carboxylase, fatty acid synthetase and stearoyl-CoA desaturase 
(Zeller et al., 2003). 
Considering the importance of mitochondria in biosynthetic pathways as well as ATP 
production, it is conceivable that Myc could be involved in mitochondrial biogenesis. The 
observation that Myc induction led to increase in mitochondrial mass and biogenesis, 
possibly through the activation of several genes such as PGC-1ß and p32, supports this 
notion (Kim et al., 2008, Li et al., 2005, Zhang et al., 2007). PGC-1ß and p32 are the 
potent inducers of mitochondrial biogenesis and respiration whose knock-down was 
shown to diminish mitochondrial function and respiration (Fogal et al., 2010, Zhang et al., 
2007). 
Myc also contributes to ribosome biosynthesis through its ability to activate gene 
transcription mediated by all three RNA polymerases I, II and III (Gomez-Roman et al., 
2003, Grandori et al., 2005). Taken together, it is proposed that Myc by stimulation of 
cell metabolism coordinates cellular growth and proliferation with cell mass. 
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1.2.2.2 S-phase entry 
Myc is an immediate early growth response gene whose induction following exposure to 
mitogens such as platelet-derived growth factor (PDGF) leads cells to enter S-phase 
(Dang, 2013). In the absence of mitogen, Myc overexpression is also able to drive 
quiescence cells to S-phase (Shichiri et al., 1993). Indeed, Myc promotes cell cycle 
progression by activation of a large number of genes such as Cyclin D1, Cyclin D2, 
Cyclin E1, Cyclin A2, Cdk4, Cdc25A, E2F1 and E2F2 (Bouchard et al., 1999, Hermeking 
et al., 2000, Zeller et al., 2003). Myc also suppresses the transcription of the cell cycle 
checkpoint genes (like Gadd45 and Gadd153) and Cdk inhibitors (like p15
INK4b
, p21
Cip1
 
and p27
Kip1
) (Gartel and Shchors, 2003, Gartel et al., 2001).  
The ability of Myc to promotes G1/S transition and DNA synthesis not only stems from 
its transcriptional role, but it was also shown that c-Myc co-localizes with the sites of 
DNA replication and physically interacts with components of pre-replication complex 
(Dominguez-Sola et al., 2007). Depletion of c-Myc indeed led to inhibition of DNA 
replication and reduced number of active replicons. Using transcriptional-silent Xenopus 
cell free extract, Dominguez-Sola et al. showed that addition of recombinant c-Myc 
protein to the Myc-depleted DNA was able to fully rescue DNA replication defect 
(Dominguez-Sola et al., 2007). Therefore, it seems that the combination of transcriptional 
and non-transcriptional activity of Myc is needed for Myc-induced S-phase entry and 
DNA replication. 
1.2.2.3 Differentiation 
Down-regulation of c-Myc is a characteristic of cells committed to undergo 
differentiation and ectopic Myc expression blocks differentiation in a number of cultured 
cells (Meyer and Penn, 2008, Oster et al., 2002). Moreover, it was shown that during 
differentiation, MAX is down-regulated (Delgado et al., 1995), suggesting that not only 
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Myc expression is reduced but also its activity is turning down by the absence of its 
partner. As terminal differentiation is usually coupled with permanent cell cycle exit, the 
differentiation impairment in Myc-induced cells has been related to the ability of Myc to 
provoke cellular proliferation. However, it was also reported that Myc, without rescuing 
the cell growth arrest and possibly by repressing the expression of master regulators of a 
differentiation state, inhibits differentiation in a number of cellular models. For example, 
it was shown that Myc inhibits the p27-mediated differentiation of human myeloid 
leukemia K562 cell line by repressing the transcription of genes involved in erythroid 
lineage differentiation rather than bypassing the G1 arrest (Leon et al., 2014).  
The importance of Myc on inhibition of differentiation was revealed particularly after the 
discovery of the role of Myc in inducing the pluripotency and maintaining the stemness 
property of “induced pluripotent stem cells” (Takahashi and Yamanaka, 2006). In 
addition, the anti-differentiation role of Myc seems to be a critical mechanism in Myc-
driven tumorigenesis, as Myc inactivation in transgenic mice led to tumor regression and 
re-differentiation of tumor cells (Arvanitis and Felsher, 2005). 
1.2.2.4 Apoptosis 
Myc also has been shown to participate in the apoptotic response under diverse cellular 
challenge, most probably to limit uncontrolled cellular growth under these conditions 
(Hoffman and Liebermann, 2008). Ectopic expression of Myc was shown to induce 
apoptosis while Myc-null cells appeared to be resistant to diverse apoptotic stimuli (Evan 
et al., 1992, Shi et al., 1992, de Alborán et al., 2004). There are several mechanisms 
found by which Myc potentiates apoptosis in the cells, the well known characterized one 
is through the activation of p53. The level of p53 protein is kept in a low level by the 
activity of the p53 negative regulator MDM2 in unperturbed cells. Myc activation leads to 
increased ARF expression which counteracts MDM2 function, resulting in increased p53 
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protein. In addition, Myc overexpression has been linked to ATM activation, a kinase that 
is critical for p53 phosphorylation and activation (Oster et al., 2002).  
It is noteworthy that p53 can cause either growth arrest or apoptosis, however deregulated 
expression of Myc was shown to abrogate p53-mediated growth arrest without affecting 
p53-mediated apoptosis. For example, Myc overexpression down-regulates several 
growth arrest genes like p21, gadd45a and gas1 that are transcriptionally activated by 
p53, favoring the p53-mediated apoptosis (Hoffman and Liebermann, 2008). 
Myc-mediated apoptotic response can also occur independently of p53. For example, 
studies in p53 wild type and p53 null mouse embryonic fibroblast (MEF) cells were 
shown that in response to Myc the pro-apoptotic BH3-only protein Bim is induced 
independently of p53 status (Hemann et al., 2005). Taken together, it seems that the 
mechanism of Myc-induced apoptosis is dependent on the cell type and the apoptotic 
stimuli.  
Myc can also disrupt the balance of pro- and anti- apoptotic factors and in this way 
sensitizes cells to undergo apoptosis. In precancerous B cells derived from EuMyc mice, 
it was shown that Myc suppresses the anti-apoptotic proteins such as BCL2 and BCL-XL 
and activates the pro-apoptotic molecules like BIM and BAX (Meyer and Penn, 2008). In 
addition Myc has been shown to have an important impact on apoptotic signaling 
pathways through the release of mitochondrial cytochrome c to the cytoplasm, triggering 
caspase activation and eventually apoptosis (Oster et al., 2002). 
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Figure 1.3. The main cellular processes regulated by Myc with some 
examples of Myc-target genes (up- or downregulated, as indicated by 
arrows) 
Adapted from “MYC: connecting selective transcriptional control to global RNA 
production” by T. R. Kress, A. Sabo and B. Amati, 2015, Nature Reviews 
Cancer, 15, p. 594.  
1.2.2.5 Cellular transformation  
Being a product of an immediate early response gene, Myc expression is rapidly elevated 
following mitogenic stimulation in quiescent cells while in dividing cells its expression is 
maintained at a constant intermediate level throughout the cell cycle. Myc mRNA and 
protein have a very short half-lives, suggesting that Myc expression is tightly regulated in 
non-transformed cells in order to respond quickly to proliferative status of the cells 
(Meyer and Penn, 2008). The physiological control that regulates Myc expression and 
activity are disrupted in many human cancers. Besides, Myc deregulation also occurs as a 
consequence of gross genetic abnormalities that affect the Myc locus (such as viral-
mediated insertional mutagenesis, chromosomal translocation and gene amplification) or 
other mechanisms that lead to aberrant Myc overexpression (transcriptional activation) of 
Myc gene (Meyer and Penn, 2008, Vita and Henriksson, 2006). However, the deregulated 
expression of Myc alone cannot transform normal cells, implying that additional 
mutations are required for Myc-induced transformation and tumor formation. For 
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example, Myc cooperates with Ras to promote cellular transformation and tumorigenesis. 
Indeed, Ras stabilizes Myc protein by phosphorylating the serine 62 residue through 
MAPK/ERK kinases and by inhibiting glycogen synthase kinase-3 (GSK3) through 
phosphatidylinisitol 3-kinase (PI3K) signaling. GSK3 can phosphorylate Myc at 
threonine 58 and thus provoke ubiquitin-mediated Myc degradation. Ras can also 
indirectly assists Myc-induced transformation. For example, several Myc target genes -
that are involved in cellular proliferation- are bound and repressed by FOXO family of 
transcription factors. Activation of Ras-downstream kinase AKT leads to FOXO 
phosphorylation and its nuclear export, thus activation of the transcription of the Myc 
target genes (Adhikary and Eilers, 2005). Besides cellular proliferation, one of the 
predominant Myc-induced pathways that has a critical role in preventing unrestricted cell 
proliferation, is Myc-induced apoptosis. Supporting this notion, many oncogenes that 
collaborate with Myc to induce tumorigenesis including Bcl-2, Ras, Raf, and v-abl have 
an anti-apoptotic functions (Oster et al., 2002). A key arm of Myc-induced apoptosis 
relies on the activation of p53 through induction of p19
ARF
 (an inhibitor of the MDM2 E3 
ligase). Spontaneous inactivation of the p19
ARF
-p53 pathway is also a frequent event in 
tumors arising in Eµ-c-myc transgenic mice (Henriksson et al., 2001). Interestingly 
enough, negative regulators of the p19
ARF
 pathway such as Bmi-1, TBX2 and TWIST 
were shown to cooperate with Myc in driving tumor formation by inhibiting the p53-
mediated apoptosis (Meyer and Penn, 2008, van Lohuizen et al., 1991). 
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1.2.3 Myc-induced DDR 
Myc overexpression is associated with the activation of a DNA damage response in a 
number of cellular systems. For example, transient Myc overexpression in U2OS cells 
caused an increase in ϒH2AX and activation of ATM/ATR-dependent checkpoints. 
Moreover, splenic B cells derived from a transgenic mouse carrying a deregulated Myc 
allele (lambda-Myc) exhibited enhanced ϒH2AX foci particularly in geminin positive 
cells (S/G2 cells) (Dominguez-Sola et al., 2007).  
Given the pleiotropic role of Myc in biological processes, it is likely that Myc induces 
DNA damage and affects genome stability in different ways. For example, Myc activation 
in normal human fibroblast cells increases ROS levels and induces DSBs and p53 
activation as well as reduces clonogenicity. Moreover, treating the cells with an 
antioxidant led to a remarkable decrease in the DNA damage and improved cell survival 
after Myc activation (Vafa et al., 2002). As Myc has a prominent role in regulating 
numerous genes involved in intermediary metabolism and particularly in mitochondrial 
oxidative metabolism, ROS may accumulate as a by-product of such unscheduled 
metabolism (Dang, 2013).  
There are also a number of studies linking the Myc-induced DNA damage response to S-
phase, highlighting the impact of Myc on origin firing and DNA replication. The induced 
DDR in Myc-overexpressing cells, at least partly, could be due to the transcriptional role 
of Myc in promoting S-phase entry and progression (Meyer and Penn, 2008). In addition, 
Gautier and colleagues, by uncoupling the transcriptional role of Myc from its non-
transcriptional function, showed that addition of recombinant Myc protein to the 
transcriptionally-compromised replicating Xenopus extracts led to replication 
perturbation and DNA damage (Dominguez-Sola et al., 2007). Further investigations by 
DNA combing experiments revealed that Myc-overexpressing cells possessed higher 
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percentage of asymmetric and unidirectional replication forks indicating that the DDR 
seen upon Myc overexpression may be a result of replication fork stalling and collapse. 
More studies revealed that Myc by acting upstream of Cdc45 -which facilitates DNA 
unwinding and the loading of DNA polymerase during DNA replication- causes an 
unscheduled origin firing and eventually leads to replicative stress (Dominguez-Sola et 
al., 2007, Srinivasan et al., 2013). 
How does unscheduled origin firing lead to DNA damage? It is proposed that higher 
levels of origin firing -for example upon Myc activation- may exhaust the dormant 
origins that serve as the backups in case of replication fork stalling or precocious 
replication termination (Rohban and Campaner, 2015). Moreover, under replication stress 
conditions, replication elongation factors such as deoxyribonucleotides (dNTPs) and the 
enzymes needed for proper fork progression like DNA topoisomerases and DNA 
helicases may become limiting, leading to inefficient DNA replication, fork stalling and 
collapse (Bester et al., 2011). Considering the fact that Myc overexpression leads to its 
pervasive binding to accessible region of the genome, it is also possible that the increase 
in DNA replication as well as transcription in Myc-overexpressing cells may lead to 
genomic instability caused by the interference between the two processes and the 
formation of structure called R-loop (Zeman and Cimprich, 2014, Gaillard et al., 2015). 
R-loop is a structure in which a nascent RNA transcript is hybridized with the template 
DNA strand, leaving the other strand unpaired and vulnerable to nuclease attack 
(Aguilera and García-Muse, 2012). This DNA-RNA hybrid may form under different 
physiological and pathological conditions. For example, R-loop forms naturally in highly 
repetitive and GC-rich immunoglobulin genes contributing to class switch recombination. 
It could also happen that R-loops arise under unusual conditions, for instance at the sites 
of paused RNA polymerase or in the case of transcription-replication collision (Santos-
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Pereira and Aguilera, 2015). Supporting this notion, it has been shown that early 
replicating fragile sites are indeed enriched in regions with high transcriptional activity 
(Barlow et al., 2013). Furthermore, the replication stress induced by Cyclin E, an 
oncogene that like Myc increases origin firing and alters replication dynamics, not only 
can be reversed by inhibiting replication initiation, but also blocking transcription rescues 
replicative stress effects and mitigates the DNA damage response. More direct evidence 
emphasizing the role of R-loop formation on Cyclin E-induced replicative stress came 
from an experiment in which overexpression of RNase H1, an enzyme required for 
resolving RNA-DNA hybrids, decreased the impaired replication fork progression in 
Cyclin E-overexpressing cells (Jones et al., 2013). Further studies have to be designed to 
confirm whether R-loop formation contributes to oncogene-induced DNA damage. 
Despite the effect of Myc overexpression on replicative stress and DNA damage 
response, Myc induction confers long-term growth advantage, suggesting that Myc-
induced replicative stress is somehow restrained or resolved in favor of an efficient 
cellular proliferation. Several studies have been conducted to find the critical molecules 
moderating Myc-induced replicative stress. One known example of such factors is WRN, 
a DNA helicase responsible for resolving DNA structures that form during S-phase, like 
those generated at stalled replication forks. WRN has been shown to co-localize with 
RPA and ATR at replication fork stalling sites and cells lacking functional WRN exhibit 
genomic instability and hypersensitivity to specific DNA damaging agents (Pichierri et 
al., 2011). In the context of Myc overexpression, WRN knock-down exacerbates Myc-
induced DNA damage response in vitro and impaired Myc-driven tumorigenesis and 
tumor growth in vivo (Moser et al., 2012, Robinson et al., 2009). As WRN is a Myc target 
genes, it seems that Myc, through regulation of the expression of WRN and by relieving 
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topological stress generated from replication stress, safeguards the cells and ensures 
proficient cellular proliferation.  
Another mechanism by which Myc copes with replication stress is to increase the rate of 
nucleotide biosynthesis. Genome-wide transcription analysis in human B cell line 
overexpressing Myc revealed a significant up-regulation of genes related to pyrimidine 
and purine metabolism besides genes involved in DNA replication and cell cycle (Liu et 
al., 2008, Zeller et al., 2003). Furthermore, Myc overexpression in cells undergoing 
replication stress induced by E6/E7 viral oncogenes or Cyclin E could rescue the 
perturbed replication -slow replication rate and enhanced ϒH2AX foci formation- 
mimicking the rescue achieved by supplementing the cells with exogenous nucleoside 
(Bester et al., 2011).  
The other well-studied example of such Myc-induced failsafe pathway is the ATR-Chk1 
signaling that was shown to alleviate Myc-induced replicative stress in vitro and promote 
malignant transformation in vivo (Murga et al., 2011). Chk1 expression is under the 
control of Myc and increased Chk1 levels have been reported in lymphomas. Inhibiting 
ATR or Chk1 in mice bearing Eu-myc lymphomas in short term triggered a strong 
increase of ϒH2AX signal and apoptosis and eventually led to tumor regression, 
suggesting that accentuating the Myc-induced RS by suppressing ATR/Chk1 limits 
transformation (Höglund et al., 2011, Murga et al., 2011, Ferrao et al., 2012). 
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1.3 Cohesin complex 
1.3.1 An introduction on the cohesin complex 
The cohesin complex was originally discovered as a major constituent of mitotic 
chromosomes required for holding post-replicative sister chromatid together. In recent 
years it was shown that, apart from its role in sister chromatid cohesion, cohesins 
participate in other processes such as DNA double strand break repair, recombination and 
gene transcription (Losada, 2014). A core of the cohesin complex consists of two 
members of the structural maintenance of chromosomes (SMC) family: SMC1 and 
SMC3. In addition, two non-SMC proteins RAD21 (Scc1 in yeast) and stromal antigen 
(SA, Scc3 in yeast) are associated with SMC1-SMC3 heterodimer to form the complex. It 
is believed that the cohesion complex embraces chromosomal DNA within a large 
tripartite ring, formed by its core subunits (Figure 1.4). Each SMC subunit is composed 
by two globular domains located at N- and C-terminal part of the protein which are 
separated by an antiparallel coiled coil domain and a flexible hinge domain in the middle 
portion of the protein. The hinge domain contains highly conserved glycine residues that 
facilitate the folding of the coiled coil region back onto itself and is also necessary for the 
formation of V-shaped SMC1/SMC3 heterodimer. The non-SMC protein RAD21, by 
bridging the two head domains of SMC1 and SMC3, acts as a ring closer, whereas SA 
does not seem to bind directly to SMC1-SMC3 heterodimer but rather associates with the 
complex through binding with RAD21 (Jessberger, 2002, Nasmyth and Haering, 2009, 
Horsfield et al., 2012). This ring shape structure of the cohesin complex is a requisite to 
almost all the functions ascribed to cohesin (Error! Reference source not found.).    
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Figure 1.4. Architecture of the cohesin complex 
The cohesin complex consists of SMC1, SMC3, RAD21 and SA subunits that 
bind together to form a tripartite ring with a diameter of about 40 nm. Cohesin’s 
binding to DNA is assisted by the cohesin loader NIPBL, whereas WAPL (wings 
apart-like protein homologue) and PDS5 promote cohesin unloading. Adapted 
from “Diverse developmental disorders from the one ring: distinct molecular 
pathways underlie the cohesinopathies” by J. A. Horsfield, C. G. Print and M. 
Monnich, 2012, Frontiers in Genetics, 3, p. 3.  
1.3.2 The role of the cohesin complex 
1.3.2.1 Cohesion and chromosome segregation 
As mentioned above, the cohesin complex is essential for sister-chromatid cohesion and 
subsequently chromosomal segregation during mitosis. Cohesin was shown to load on 
chromatin in G1/S phase by the aid of the cohesin loader NIPBL, allowing the 
establishment of sister-chromatid cohesion in S-phase and maintenance of chromatid 
cohesion during the G2 phase of the cell cycle (Losada, 2014).  
Cohesin functions are also regulated by a number of cohesin-binding proteins such as 
Wapl, Pds5 and sororin as well as modifications such as phosphorylation, acetylation and 
proteolysis. The ESCO1 and ESCO2 acetyl transferases have been shown to be needed 
for SMC3 acetylation in mammalian cells. ESCO1/2 were suggested to be recruited to the 
fork by interaction with PCNA and the replication factor C (RFC)-CTF18 clamp loader 
(RFC
CTF18
). In vertebrates, SMC3 acetylation enables the binding of sororin to Pds5, 
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which counteracts Wapl’s ability to remove cohesin from chromatin (Losada, 2014). In 
this way, SMC3 acetylation was suggested to convert cohesin ring that may obstruct the 
replication fork to an open ring, thus permitting fork advancement (Terret et al., 2009). In 
addition, several models have been proposed related to the interplay between replication 
and cohesin during S phase. One model proposes the involvement of specific replication 
factors such as translesion DNA polymerase that may facilitate DNA synthesis through 
sites of cohesin binding. Another model simply relies on the structural property of the 
cohesin ring whose large diameter (40 nm) may allow the replication machinery to pass 
through (Jessberger, 2003, Nasmyth and Haering, 2009). 
In vertebrate cells, during prophase, the vast majority of the cohesin complex is 
dissociated from chromosomes by Wapl. This process is mediated by Plk1-dependent 
phosphorylation of SA2. The residual cohesins remain mainly associated with the 
centromeric regions which is protected from Wapl and Plk1 by shugoshin-protein 
phosphatase 2A complex. During the metaphase-anaphase transition, cysteine protease 
Separase is activated and by cleaving RAD21 leads to dissolution of the remainder 
cohesin complex allowing chromosome separation (Jessberger, 2002, Losada, 2014).  
1.3.2.2 DNA damage response, repair and recombination  
As cohesins act through a ring-shaped structure, it is conceivable to assume that they may 
also have a role in DNA recombination and repair, possibly by aligning and juxtaposing 
the two anti-parallel DNA strands. Indeed, SMC1 and SMC3 -the core components of the 
cohesin complex- were identified as two previously unknown subunits of the 
recombination protein complex RC-1. This complex by possessing subunits such as DNA 
polymerase epsilon, DNA ligase III and an endonuclease was shown to catalyze cell-free 
DNA strand transfer and DNA gap repair (Jessberger et al., 1993, Jessberger et al., 1996). 
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Cohesin appeared to also have a role in recombination during meiosis. In S. cerevisiae 
SMC3 and the meiotic homologue of RAD21, REC8, were shown to be closely 
associated with the synaptonemal complex (SC) until late prophase when REC8 
dissociates from the chromosomal arms (Klein et al., 1999). The same observation was 
also made in mammalian cell, where SMC1 and SMC3 exhibited to co-localized with SC 
proteins SCP2 and SCP3 (Eijpe et al., 2000, Eijpe et al., 2003). In C. elegans, Rec8 
depletion resulted in deficient chromosome synapsis in pachytene and pre-mature 
chromosome segregation in diakinesis suggesting that Rec8 has a role in meiotic 
homologous recombination (Pasierbek et al., 2001). 
The cohesin subunits have also been shown to be involved in DNA damage response (Wu 
and Yu, 2012). Rad21 was originally identified in S. pombe as one of the Rad genes 
whose mutation in yeast led to cell sensitivity to DSBs (Birkenbihl and Subramani, 1992). 
The recruitment of the cohesin subunits to DSBs in human cells was shown by 
immunofluorescence, where SMC1 was shown to localize to laserbeam-induced DNA 
damage sites in a Mre11/Rad50-dependent manner (but not ATM or Nbs1) (Kim et al., 
2002a). This was further supported by immunoprecipitation studies, demonstrating the 
cohesin enrichment around the DSBs generated by I-SceI cleavage (Potts et al., 2006, 
Ünal et al., 2004).  
Moreover, in 2002 Kim et al. identified two serine residues in SMC1 (Ser 957 and Ser 
966) that become phosphorylated by ATM upon ionizing radiation. Exposure of cells to 
ultraviolet radiation or the DNA replication inhibitor hydroxyurea (HU) also yielded 
SMC1 phosphorylation even in ATM deficient cells, probably through ATR kinase 
activity (Kim et al., 2002b). In another study, Kitagawa et al. observed that the level of 
the SMC1 phosphorylation, likewise NBS1 and H2AX phosphorylation, increased in an 
IR dose-dependent manner (Kitagawa et al., 2004). This data together with the detection 
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of phospho-SMC1 at the DNA damage foci by immunofluorescence, indicate that most 
likely SMC1 is phosphorylated and acts at the site of DNA damage. 
SMC1 mutants in the phosphorylation sites (Ser 957 and Ser 966) exhibited impaired S-
phase arrest after IR, though cells were arrested in G2 phase, suggesting that the lack of 
IR-induced S-phase checkpoint results in accumulation of cells in G2 over time (Kim et 
al., 2002b). Furthermore, by using cells lacking functional Nbs1 (NBS1-LB1 cell) or 
BRCA1 (HCC1937 cell) Kim and others showed that optimal phosphorylation of SMC1 
is dependent on the presence of Nbs1 and BRCA1 at the site of DNA damage (Kim et al., 
2002b). Although there are some discrepancies between different studies, these may be 
due to different DDR pathways activated by DNA damage stimuli and the crosstalks 
between ATM and ATR. Altogether, these results proposed a new function for SMC1 and 
showed that it can play a role in DNA damage-induced S phase checkpoint and 
modulation of radiosensitivity.  
While it is not clear whether IR-induced phosphorylated SMC1 functions through 
canonical cohesin complex or as a single protein, overexpression of dominant-negative 
mutants for SMC1 phosphorylation did not raise significant increase in chromosomal 
breaks after IR, separating radiosensitivity phenotype from chromosomal breakage 
phenotype in these cells (Strom et al., 2004). There are also studies emphasizing on the 
role of other non-SMC subunits in DNA damage, reinforcing the role of cohesion on 
DNA damage response. For example, phosphorylation of RAD21 by Chk1 was shown to 
be critical for RAD21 acetylation and cohesion establishment in DNA damage sites 
(Heidinger-Pauli et al., 2008, Heidinger-Pauli et al., 2009). In addition cohesion-
establishment factor, sororin, was shown to be required for efficient DNA damage repair 
during G2 in HeLa cells (Schmitz et al., 2007). Despite all these studies shedding light 
into the role of cohesin in DDR, a lot of unresolved questions left behind. For example, 
 31 
 
what are the exact functions of the SMC proteins in DNA damage response and DNA 
repair? Do they simply provide a structural support to promote DNA repair, or do they 
preferentially bind to and thus mark the sites of DNA damage to recruit other DDR-
proteins? As SMC proteins are the prominent protein whose function was evaluated in 
these studies, it is still not clear whether the role of SMC in DNA damage can be 
attributed to other subunits of the cohesin complex, whether these functions are carried 
out by SMC proteins alone or whether they act in a different unknown protein complex 
should be further studied. 
1.3.2.3 Regulation of gene transcription 
The cohesin complex has also a role in transcriptional regulation, in part due to its 
interaction with CCCTC-binding factor (CTCF). CTCF is the main insulator protein in 
vertebrates and is capable of activating or repressing gene expression by facilitating 
interactions between transcription regulatory sequences (Ong and Corces, 2014). 
Although not always bound to CTCF on chromatin, cohesins have been shown to stabilize 
CTCF-mediated chromosomal interactions and thus facilitating CTCF function. Down-
regulation of cohesins resulted in the disruption of CTCF-mediated intrachromosomal 
interactions and affected gene expression. For example, in mouse embryonic stem (ES) 
cells the TATA-binding protein-associated factor 3 (TAF3), a component of the promoter 
recognition complex TFIID, not only is bound to promoters but also is found at CTCF- 
and cohesin-bound distal sites. By promoting the formation of a loop between two 
sequences, it is proposed that CTCF and cohesin tether distal regulatory elements, such as 
endodermal enhancers in this case, to their target promoters (Ong and Corces, 2014, 
Wendt et al., 2008).  
Cohesins and the cohesin loader NIPBL were also found in association with mediator 
complex and RNA polymerase II (but not CTCF) at the enhancers and the core promoter 
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sites of actively transcribed genes in ES cells. Using 3C technology Kagey et al., 
observed an increased interaction frequency between core promoter and the enhancer of 
the pluripotency genes in ES cells compared to MEFs where these genes are silent and are 
not occupied by mediator and cohesin. Therefore, it is suggested that cohesins through 
their role in DNA loop formation may favor physical association of distal regulatory 
elements to the core promoter thus contributing to gene regulation (Kagey et al., 2010). 
1.3.2.4 DNA replication 
The cohesin complex was found to interact with components of the pre-replication 
complex, such as MCM proteins (Guillou et al., 2010). Furthermore, cohesins down 
regulation slowed down S-phase progression and this was shown to be independent of 
sister chromatid cohesion, regulation of gene transcription and checkpoint activation. 
Monitoring DNA replication by DNA combing showed a reduced fork density (number of 
forks divided by the total length of DNA fibers normalized by the percentage of cells in 
S-phase) in Rad21-depleted cells compared to control cells whereas the fork velocity was 
similar, indicating that the S-phase delay is most likely due to a reduced frequency of 
origin firing. Moreover, Genome-wide enrichment of cohesins, exhibited a significant 
enrichment of the cohesin complex at the genomic intervals located at origins rather than 
regions not harboring replication origins (Guillou et al., 2010, MacAlpine et al., 2010). 
Considering the architectural role of the cohesin complex, it is proposed that potential 
replication origins within a DNA region are grouped in a rosette-like structures where the 
replication factories tethered and make a favorable environment for DNA replication. 
Disrupting the cohesin-mediated structures caused formation of larger chromosomal 
loops, shown by increased halo radius signal, and reduced frequency of origin firing 
(Guillou et al., 2010, Losada, 2014). 
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Cohesin was shown to have a role in replication of telomeric regions. MEFs lacking 
cohesin subunit SA1 (which is responsible for telomeric cohesion) showed reduction in 
the fraction of replicating telomeres and defects in chromosome segregation (Remeseiro 
et al., 2012). 
 
Figure 1.5. Cohesin functions 
(A) Cohesion-dependent functions. The cohesin complex by embracing the 
double strand DNA in the replication sites is important to stabilize the stalled 
replication forks and to facilitate replication fork restart. In the case of double 
strand break, the cohesin complex can also hold two sister chromatid together 
and promotes homologous recombination-mediated repair. In mitosis, cohesin-
mediated cohesion ensures faithful chromosome segregation. (B) Cohesion-
independent function. The cohesin complex by establishing and maintaining the 
large chromosomal interaction is important for genome organization as well as 
promoting transcription and replication. Adapted from “Cohesin in cancer: 
chromosome segregation and beyond” by A. Losada, 2014, Nature Reviews 
Cancer, 14, p. 392. 
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1.3.3 Cohesins in human diseases 
Human diseases caused by mutations in genes associated with the cohesin complex are 
termed cohesinopathies. One of such diseases is the Roberts/SC phocomelia syndrome 
that is caused by mutations in the acetyltransferase ESCO2 that is needed for cohesion 
establishment. Heterozygous mutations in SMC1, SMC3 or NIPBL are the cause of 
another cohesinopathy called Cornelia de Lange syndrome (CdLS). Cohesionopathies are 
characterized by a variety of developmental abnormalities such as growth failure, mental 
retardation, limb defects and craniofacial anomalies. In addition, cells derived from 
patients with cohesinopathies are hypersensitive to variety of DNA-damaging agents like 
mitomycin C and camptothecin, presumably related to the role of cohesin in homologous 
recombination repair. However, these cells do not exhibit massive defect in sister 
chromatid segregation, instead the developmental defects in the patients suggest that 
cohesin is crucial for developmental gene expression programs during embryogenesis 
(Bose and Gerton, 2010). Indeed gene expression profiling in several mutant cell lines 
derived from CdLS patients identified around 400 deregulated genes involved in 
embryonic and tissue development, hematological and immune system development. 
Furthermore, not only cohesins have been shown to preferentially bind to promoter 
regions of active genes, but also there was a correlation with reduced cohesin binding in 
the vicinity of misregulated genes in mutant cells, suggesting that cohesin may play a role 
as a transcription factor (Liu et al., 2009). The findings of transcription factor dense 
cluster forming almost invariably around cohesins also provided evidence for the role of 
cohesin in mediating gene expression presumably by formation of loops between 
enhancers and promoters or stabilization of transcription factor binding.  
Cohesins mutations are also found in a variety of human cancer samples. For example, 
mutations in STAG2 were found in urothelial bladder cancer, glioblastoma, Ewing’s 
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sarcoma and melanoma. Also mutations in genes encoding the cohesin subunits and 
NIPBL were identified in colorectal cancer, AML and other myeloid neoplasms. Overall, 
mutations in STAG2 are often truncating and usually affect one allele. Considering that 
STAG2 gene in located on the X chromosome, the high rate of mutation in this gene may 
not have a huge impact on chromosome segregation, as SA1 can partially compensate this 
loss. In contrast to STAG2, mutations in other cohesin genes including SMC1 and NIPBL 
are mostly missense. The consequence of these missense mutations in protein function 
still is not clear (Losada, 2014). 
It is mainly believed that cohesins dysfunction may accelerate tumorigenesis by 
increasing genome instability. Although chromosome missegregation and the subsequent 
aneuploidy could be deleterious for cell survival, it may also be beneficial for tumor 
development. However, a study in yeast revealed that sister-chromatid cohesion and 
chromosome segregation are not affected even when cohesin levels are reduced to 13% of 
wild-type levels. Studies on cells derived from heterozygous NIPBL mice, which 
recapitulates several phenotypes of CdLS, also showed normal mitosis, instead 
transcription was disrupted at several loci (Heidinger-Pauli et al., 2010). These results 
suggest that transcriptional regulation could be more sensitive to the reduction in the 
levels of functional cohesin present in the cell, proposing that mutations in cohesin may 
promote tumorigenesis mainly by affecting the transcription of oncogenes and tumor 
suppressor genes. 
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Aim of the study 
In the context of Myc-induced DNA damage response, we propose that Myc, when 
overexpressed, may co-opt several intracellular pathways that may function to protect 
cells from excessive replicative stress and DNA damage, thus allowing efficient cellular 
proliferation. The identification of such pathways will not only improve our mechanistic 
understanding of Myc-induced cellular transformation, but may also have relevant 
clinical implications to selectively target Myc-overexpressing cancer cells.  
The aim of the current study was to identify the modulators of Myc-induced DDR by 
means of RNAi screen followed by further characterization of the mechanism of action of 
some hits. 
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2 Materials and methods 
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2.1 siRNA screen 
2.1.1 MEF immortalization 
R26-MycER primary mouse embryonic fibroblast (MEF) cells were spontaneously 
immortalized using 3T3 protocol. Briefly primary MEF cells growing in a 10-cm dish 
were washed with PBS (Lonza
®
) and trypsinized with 1 ml of 0.05% trypsin-EDTA 
(Lonza
®
). After cell detachment, trypsin was diluted into 5 ml of growth media and the 
cells were counted by Neubauer chamber. 3×10
5 
cells were seeded in a 6-cm dish 
(Nunc
TM
) and were grown in normal oxygen (20% O2) incubator. Subsequent passages 
were done every 3 days in a manner described above. Growth curve was determined from 
cell count at each passage. The immortalized cells were further subcloned by limiting 
dilution following colony picking and expansion.  
2.1.2 Optimization of siRNA reverse transfection conditions 
The efficiency of siRNA delivery into Bz1 R26-MycER MEF cell line was tested by 
comparing the performance of Lipofectamine RNAiMAX (Lifetech) and DharmaFECT1 
(Dharmacon, Thermo Fisher Scientific) transfection reagents in 96-well plate format. In 
brief, three different concentration of the transfection reagents (0.1, 0.2 and 0.3 µl per 
well) were used to reverse transfect three different cell densities (2000, 3000 and 5000 
cells per well). A toxic siRNA (siTOX, Dharmacon, Thermo Fisher Scientific) was used 
to assess the transfection efficiency based on cell death induction. For reverse 
transfection, the transfection reagent was diluted in an appropriate volume of Opti-MEM 
(Gibco, 20 µl per well) and then transferred to the wells of a 96-well plate. After 5 
minutes incubation time, 30 µl of diluted siRNA in Opti-MEM was added to the 
transfection reagent in the wells and mixed. The lipid-siRNA complex was allowed to 
form during 20 minutes incubation at room temperature. Afterwards, 50 µl of cell 
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suspension (in 2X medium) was added to the complex to reach the final volume of 100 
µl. All the siRNAs were used at 25 nM final concentration during transfection. Forty-
eight hours post transfection, cell viability was measured by MTT (3-[4, 5-
dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide) assay (Sigma).  
Once the best performing transfection reagent defined, the assay was scaled down into 
384-well plate format. To this purpose, first the optimal cell density in 384-well format 
was determined by seeding different cell numbers (400, 625, 800, 1250, 1600 and 2500 
cells/well) in a 384-well plate and measuring the cell growth at different time points using 
the CellTiter-Glo assay (Promega). The selected cell density was then used for testing 
different volumes of DharmaFECT1 reagent per 384-well (0.2, 0.15, 0.12 and 0.1 µl). 
The toxic siRNA (siTOX) and a pool of non-targeting siRNAs (siGENOME Non-
Targeting siRNA Pool #2, Dharmacon, Thermo Fisher Scientific) were used as the 
positive and negative controls respectively.  
2.1.3 Automated high-throughput siRNA transfection 
The mouse siGenome SMARTpool library was obtained from Dharmacon (Thermo 
Fisher Scientific) in 384-well format. Each well in the library contains a pool of four 
distinct siRNA oligos targeting different sequences of the target transcript. Five library 
plates were analyzed targeting a total of 1400 druggable genes plus positive controls for 
monitoring transfection efficiency (SMARTpool siGENOME Plk1 siRNA), assay 
specific positive control (SMARTpool siGENOME Rad21 siRNA) and a siRNA targeting 
the Renilla Luciferase gene (siGENOME Rluc siRNA) as negative control for data 
normalization.  
The esiRNA custom libraries were purchased from Sigma (MISSION
®
 esiRNA, Sigma) 
in 384-well format. esiRNAs are endoribonuclease-prepared siRNA pools comprised of a 
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mixture of siRNAs that all target a same gene. Control esiRNAs targeting mouse Plk1, 
Kif11, Rad21 and Rluc were purchased in individual tubes and included in the final 384-
well plates.  
Silencer pre-designed siRNA library was obtained from Ambion (Silencer®, Ambion) in 
384-well plate. Three different individual silencer siRNAs were chosen for each gene. 
Silencer siRNAs against mouse Kif11, Rad21 (#150458) and negative control #2 were 
also used as controls. 
For screening, 800 Bz1 R26-MycER immortalized MEF cells/well were reverse-
transfected in 384-well black, gelatin-coated optical plates (Corning) using the Freedom 
EVO automated liquid handler system (Tecan) with 0.13 µL/well of DharmaFECT1 
transfection reagent (Dharmacon, Thermo Fisher Scientific) and 25 nM Dharmacon 
SMARTpool or Ambion silencer siRNA or 50 nM of Sigma esiRNA. After transfection, 
cells were cultured for 48 hours under standard conditions (37°C in humidified 
atmosphere, with 5% CO2), in the SteriStore automated incubator (HighRes 
Biosolutions). A total of 6 replicates plates (3 ethanol- and 3 OHT-treated) were 
transfected for each of the library plates.  
2.1.4 Fixing and immunofluorescence staining 
Forty-eight hours post siRNA transfection, cells were fixed by adding 40 µl of 4% 
Paraformaldehyde (PFA) directly to the medium to reach a final concentration of 2%. The 
plates were then incubated at room temperature for 15 minutes. After that, the medium 
was aspirated and the plates were washed twice with PBS. Then cells were permeabilized 
by adding 20 µl of 0.1% Triton X-100 (in PBS) to each well. After 10 minutes, cells were 
washed with PBS and blocked with 20 µl of blocking buffer (PBS + 2% BSA + 10% goat 
serum) for 30 minutes. Cells were then rinsed twice with PBS and incubated with 25 µl of 
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anti-phospho-Histone H2AX (Ser139) antibody (Merck Millipore, Cat#05-636) dilution 
(1:1500 in 2% BSA) for 1 hour at room temperature. Afterwards, cells were washed two 
times with PBS and then incubated with 25 µl of secondary antibody dilution (1:400 
Alexa Fluor® 488 goat anti-mouse antibody in 2% BSA, Invitrogen Cat#A11001). and  
DAPI (1:4500 in PBS) for 1 hour. Following 3  washes with PBS, 70 µl of PBS was left 
in the plates and the plates were sealed and stored at 4°C until imaged. 
2.1.5 Image acquisition and processing 
Cells were imaged on the Olympus ScanR wide-field microscope which allows fully 
automated image acquisition. ϒH2AX-Alexa 488 fluorescence was acquired using 
BP470-495 excitation filter and BP510-550 emission filter (U-MNIBA3; Olympus) 
meanwhile DAPI was acquired by BP360-370 excitation filter and BP420-460 emission 
filter (U-MNIBA3; Olympus). Image acquisition was done with 10X objective, and six 
different fields of view were recorded for each well, thus covering most of the entire area 
of a 384-well format.  
The acquired images were analyzed using a custom image analysis algorithm (by Dr. 
Adrian Andronache in IIT Screening unit, available upon request), developed and 
executed in the Acapella software development/run-time environment (Perkin Elmer). 
The algorithm used some Perkin Elmer proprietary procedures, such as the nuclei 
detection on the DAPI channel. The image analysis procedure was run on every single 
field of view acquired on two channels, and eventually merged the results for each 
individual well by summing or averaging single parameters, according to their definition 
(see the following paragraphs, provided by Dr. Adrian Andronache). 
Step 1: Background removal and uneven illumination correction 
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The image analysis algorithm starts with the background removal and uneven 
illumination correction for all the images on both input channels. This step is performed 
using a sliding parabola transform which divides the input image into two parts: 
background and foreground (signal ). The curvature of the parabola was set up to 1/500 
pixels, so that it does not affect the real signal from the images. 
Step 2: Nuclei segmentation and local background definition 
First, using Perkin Elmer (PE) proprietary algorithms, we identified all the individual 
nuclei from the DAPI channel. Then we defined the local background of every nucleus 
using the Voronoi tessellation. Voronoi tessellation divides the image space by defining 
region boundaries equally distanced from the neighboring given centers (i.e. nuclei). In 
order to not extend too much from the nuclei, a maximum border distance of 50 pixels 
away from the nuclei was imposed. Once the nuclei were segmented and their Voronoi 
regions were estimated, we defined individual foreground and background masks for 
every nucleus, these masks were further used to extract phenotype descriptors for every 
cell. 
Step 3: Preliminary features extraction 
For all the detected objects (nuclei having both a foreground and an associated local 
background), a series of basic parameters were directly extracted or derived from the 
different images to describe the morphology and phenotype of individual cells. First, from 
the nuclei segmentation we estimated the radius, the area, and the shape of every single 
nucleus. Second, the nuclear DAPI intensity was defined as the difference between the 
average intensities of each individual foreground and background nuclei. The DNA 
content was defined as the product of the DAPI intensity and the nuclear area. Third, 
from the Alexa 488 channel we estimated all the ϒH2AX related features as described in 
the following paragraph. 
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Step 4: ϒH2AX foci and pan-nuclei definition 
The ϒH2AX foci were defined using a local adaptive thresholding approach. Using the 
previously defined nuclear masks, we calculated the average Alexa 488 intensities of 
every nucleus in the population of negative controls (siRluc). This resulted in the 
threshold that differentiates background from ϒH2AX signal. Further on, this threshold 
was used to segment the ϒH2AX foci from the Alexa 488 channel on every single 
nucleus (within the foreground masks) on all the screened wells. A local adaptation of the 
threshold was performed for every single nucleus, by correcting for the Alexa 488 
background level extracted from the individual local background mask. All nuclei with 
ϒH2AX foci covering more than 70% of their surface were declared (labeled) as “pan-
nuclear ϒH2AX”.  
Step 6: Phenotype descriptive parameters 
For every single well, the information extracted from all the 6 field of view was finally 
integrated and the following main phenotype description parameters reported: 
N°_Of_Nuclei: the total number of nuclei from all the 6 fields of view, remained 
after the different filtering described previously; 
N°_Of_PanPosNuclei: the total number of pan-nuclear ϒH2AX nuclei from all 6 
fields of view; 
Percent_Of_PanPos: the percent of pan-nuclear ϒH2AX nuclei with respect to the 
total number of nuclei from all 6 fields of view; 
Dapi_Intensity: the average DAPI intensity of all detected nuclei; 
DNAContent: the average DNA content of all detected nuclei; 
NuclearArea: the average nuclear area of all detected nuclei; 
ϒH2AX_Intensity: the average Alexa488 intensity of all detected nuclei; 
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ϒH2AX_AreaCoverage: the average ϒH2AX foci area coverage of all detected 
nuclei. 
Each well of an assay plate was associated a phenotype descriptive vector (an array of the 
8 previously main parameters) and eventually tabulated and associated the biological and 
technical annotation according to the plate-layout design and siRNA-database definition. 
2.1.6 Statistical data processing and analysis 
The statistical data processing and analysis was performed independently on two of the 
main phenotype descriptor parameters extracted by the image analysis: the viability (i.e. 
the N°_Of_Nuclei) and the DNA damage response (DDR) (the percentage of pan-nuclear 
ϒH2AX nuclei: Percent_Of_PanPos). The data of each screened siRNA was available in 
triplicates sample values for each of the two chemical treatments ethanol (EtOH) and 
OHT. Each assay plate had a series of control wells (with negative and positive controls 
for transfection and assay-specific positive control ) and multiple experimental samples. 
From here on, the data of a single well will denote the specific parameter value of any 
well, independent from nature of the transfection reagent class (negative or positive 
controls or experimental samples). 
The statistical data processing and analysis is organized in the following 5 main steps: 
intra plate normalization of raw data (on each individual assay plate); 
intra-treatment data dimensionality reduction;  
inter-treatment data dimensionality reduction; 
hit metric estimation; 
hit calling. 
The intra-plate normalization of raw data ensures the removal of inter-plate variability. 
This operation is done on every assay plate with respect to the median data of all the 
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negative controls present on the analyzed plate (siRluc). The normalization procedure was 
performed only on the viability parameter, as the percent of pan-nuclear ϒH2AX nuclei is 
internally normalized to the number of nuclei of a given well. All the samples presenting 
a very low viability (i.e. less than 100 nuclei within a well) were discarded from 
following statistical data processing and analysis of both viability and percent of pan-
nuclear ϒH2AX parameters.  
The intra-treatment data dimensionality reduction merges the replicates (triplicates) 
values of the wells on the assay plates. This operation estimates the median of the 
transfection samples replicates in order to assign one single data value for each well 
(siRNA) within each experimental condition (EtOH and OHT treatments).  
The inter-treatment data dimensionality reduction is the operation of combining and 
confronting the parameter values of single wells in between the different experimental 
conditions. As such, the viability-ratio was estimated for all the wells by dividing 
normalized viability in OHT-treated to EtOH-treated samples. At the same time, the 
DDR-gain was estimated as the difference between the percent of pan-nuclear ϒH2AX 
nuclei in OHT-treated and the EtOH-treated samples. 
Both viability-ratio and DDR-gain previously estimated underwent the classical Z-score 
hit metric estimation. Using a plate-wise approach, the primary screen data was using as 
reference the entire population of experimental samples, using the assumption that most 
of the siRNAs have a null effect. Similarly, using the plate-wise approach, the hit metrics 
applied on the data of the deconvolution/validation screens used as reference the 
population of negative samples present on the analyzed plate.  
The final step of the statistical data processing and analysis is the hit calling. The Z-score 
≤ -2 and Z-score ≥ 1.25 was set to identify the set of genes whose knockdown decreased 
the viability ratio of OHT versus EtOH-treated cells (called synthetic lethality hits) and 
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the set of genes whose knockdown increased the viability ratio of Myc-activated cells 
compare to non Myc-activated control cells (called synthetic viability hits) respectively. 
For DNA damage response (DDR) hit identification, four different methods, all 
established from median absolute deviation (MAD)-based Z-score, were evaluated in a 
pilot test composing 280 genes. The evaluated methods were: (1) difference in ϒH2AX 
enhancement in OHT samples compared to EtOH-treated samples, (2) robust regression, 
(3) ratio of ϒH2AX in EtOH versus OHT-treated samples and (4) principal component 
analysis (PCA). Eventually we chose “difference in the percentage of ϒH2AX 
enhancement” as a standard method for the analysis of all libraries. Hits were called 
DDR-up if the Z-score of DDR-gain  (OHT-EtOH) in triplicates, was ≥ 2. 
2.1.7 Enrichment analysis 
Functional classification was performed using PANTHER (http://pantherdb.org), DAVID 
(https://david.ncifcrf.gov) and Ingenuity Pathway Analysis (IPA, 
http://www.ingenuity.com) tools.  
2.2 Cell culture  
2.2.1 Cell infection 
10 µg of the retroviral plasmids together with packaging plasmids were used to transfect 
Phoenix Ecotropic or Amphotropic packaging cells (10-cm dish) using Calcium 
Phosphate. 24 hours post transfection the medium was replaced with new medium. The 
virus supernatant was collected 48 and 72 hours post transfection and filtered through a 
0.45 µm filter. Next, the medium of the target cell was replaced with the virus 
supernatant, polybrene was immediately added to the medium (8 µg/ml) and the cells 
were put in the 37°C incubator for at least 3 hours. Afterwards the medium was replaced 
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by fresh medium. Depending on the cell density and growth, 24-48 hours after incubation, 
cells were trypsinized and split into antibiotic-containing medium.  
2.2.2 Cell lines and culture conditions 
Immortalized R26-MycER MEF cell lines (Bz1 and Bz5), U2OS and U2OS-MycER cells 
were cultured in DMEM (Lonza
®
) containing 10% FBS supplemented with 1% penicillin, 
1% streptomycin and 2 mM Glutamine in 5% CO2 incubator. Primary MEFs were 
cultured in DMEM containing 10% FBS supplemented with 1% penicillin, 1% 
streptomycin, 2 mM Glutamine, 1% non essential amino acids and 25 µM ß-
mercaptoethanol under hypoxia condition (3% O2). 
2.2.3 siRNA transfection 
For transfection, cells were grown in media without antibiotics. Bz1 R26-MycER MEF 
cell line and U2OS cells were reverse-transfected with DharmaFECT1 (Dharmacon, 
Thermo Fisher Scientific) and Lipofectamine RNAiMAX (Lifetech) transfection reagent 
respectively, according to the manufacture’s instruction.  All siRNAs were used at 25 nM 
final concentration during transfection. OHT was added in the time of transfection at 400 
nM final concentration. 
2.3 Cell survival assay 
MTT assay was done by adding 20 µl of sterile MTT solution (5 mg/ml MTT, Sigma, in 
PBS) to 100 µl of medium in each well of 96-well plate. The plate was incubated for 4 
hours at 37°C cell culture incubator. After this time the medium was removed and 150 µl 
of DMSO was added to each well. The plate was then agitated on an orbital shaker for 15 
minutes and then was diluted (if necessary) and read at 590 nm with luminometer. An 
extra well containing no cells with medium was used as a blank for normalization. 
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CellTiter-Glo® (Promega) assay was performed according to the manufacturer’s 
protocol. Briefly a vial of CellTiter-Glo® buffer was thawed and was equilibrated to 
room temperature. Then the appropriate volume (10 ml) of the buffer was transferred to 
the bottle containing CellTiter-Glo® substrate. After mixing, an appropriate volume of 
the CellTiter-Glo® reagent (the volume equal to the volume of the medium) was added 
directly to the room temperature equilibrated opaque-walled white plate (Costar®) and 
the contents were mixed for 20 minutes on an orbital shaker. The luminescence was then 
read by the CellTiter-Glo protocol in Promega GloMax® reader. 
2.4 Flow cytometry and cell cycle analysis 
Asynchronous growing cells were pulsed labeled with bromodeoxyuridine (brdU) for 30 
minutes prior to harvesting. As a negative control, no BrdU control was included. Cells 
were trypsinized, fixed with ice-cold 70% ethanol and stored at 4°C until further analysis. 
Cells were then washed in PBS + 2% BSA and treated with 1 ml of 2N HCl for 20 
minutes to expose labeled DNA. HCl was then neutralized with addition of 3 ml of 
sodium borate (0.1 M, pH 8.5) for 2 minutes. After spinning down the cells were washed 
twice with PBS and the pellet was resuspended in anti-BrdU antibody (1:5, BD 
Biosciences) and incubated for 1 hour at room temperature. Cells were then quickly 
washed and incubated for 30 minutes with secondary fluorescence labeled antibody. After 
washing, cells were resuspended in propidium iodide (2.5 µg/ml) + RNase A (250 µg/ml) 
and kept at 4°C overnight.  
For ϒH2AX/DNA synthesis staining, cells were pulsed with EdU (5-ethynyl-2´-
deoxyuridine, 10 nM) for an appropriate time and then were trypsinized and fixed with 
ice-cold 70% ethanol. Fixed cells were then washed with PBS containing 1% BSA. Then 
cells were permeabilized with 100 µl of  0.25% Triton-X 100 in PBS for 10 minutes at 
room temperature. After a washing step with PBS, the cell pellet was resuspended in 500 
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µl of PBS + 10% Goat serum. Following 30 minutes incubation, the cells were stained 
with mouse anti phospho-H2AX (1:200 in PBS + 1% BSA) for 2 hours. Then cells were 
washed once with PBS + 1% BSA and spun down. The cell pellet was resuspended in 
secondary goat anti-mouse FITC antibody (1:50 in PBS + 1% BSA) and incubated for 1 
hour at room temperature. After a washing step, cell pellet was resuspended in 200 µl of 
Click-iT® (Life technologies) reaction solution (175 µl PBS + 4 µl CuSO4 + 1 µl Alexa 
647 azide + 20 µl 1X Click-iT EdU buffer additive). After 30 minutes incubation at room 
temperature, cells were washed with PBS + 1% BSA and the pellet was resuspended in 
500 µl of propidium iodide (2.5 µg/ml) + RNase A (250 µg/ml) and stored at 4°C until 
FACS analysis. Cell cycle analysis performed on FACSCalibur flow cytometer using Cell 
Quest Pro software. Flow cytometry data analysis was performed using FlowJo software 
(vX.0.7).  
2.5 Immunostaining and Immunoblotting 
For immunostaining, growing cells on coverslips were first washed twice with PBS and 
then fixed with paraformaldehyde (4%) for 10 minutes at room temperature. For RPA 
staining pre-extraction was carried out before fixation, by treating the cells first with ice-
cold cytoskeleton buffer (10 mM Pipes pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM 
MgCl2, 1 mM EGTA and 0.5% Triton-X 100) for 5 minutes on ice and then with ice-cold 
cytoskeleton stripping buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1% 
Tween 40 (v/v) and 0.5% v/v sodium deoxycholate). After 5 minutes incubation on ice, 
cells were rinsed three times with ice-cold PBS and then fixed with 4% paraformaldehyde 
for 10 minutes at room temperature.   
Fixed cells were then permeabilized with 0.2% Triton-X 100 in PBS for 10 minutes at 
room temperature. After a brief wash with PBS, the cells were incubated with blocking 
solution (2% BSA in PBS) for 30 minutes. Primary antibodies were diluted in PBS 
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containing 1% BSA. Incubations with the primary antibodies were performed at room 
temperature for 1 hour. Cells were then washed and incubated with secondary 
fluorescently labeled antibodies for 45 minutes. DAPI staining (1:5000) was applied for 5 
minutes at room temperature to stain DNA. After a washing step with PBS, coverslips 
were dried and mounted on Mowiol-based mounting media.  
For BrdU immunofluorescence, after permeabilization, cells were first treated with 
DNaseI (Neb) at 37°C for 30 minutes and then were incubated with anti-BrdU antibody. 
For western blotting, cells were washed twice with ice-cold PBS and then lysed in an 
appropriate volume of lysis buffer containing 20 mM Hepes pH 7.5, 0.5 M NaCl, 5 mM 
EDTA, 10 % Glycerol and 1% Triton-X 100, supplemented with protease and 
phosphatase inhibitors. After sonication, lysates were centrifuged and the supernatant was 
recovered. The protein concentration was determined according to Bradford (Bio-Rad 
Laboratories). Cell extract was separated on 4-15% gradient precast TGX
TM
 
polyacrylamide gel (Bio-Rad Laboratories) and was blotted onto nitrocellulose membrane 
using Trans-Blot® Turbo
TM
 transfer system (25 V, 1 A, 30 minutes). Following 1 hour 
blocking in TBST containing 5% BSA, blot was incubated with primary antibody for 
overnight at 4°C. Secondary peroxidase-coupled antibodies were incubated with the blot 
at room temperature for 1 hour. ECL-based chemiluminescence (Bio-Rad Laboratories) 
was detected on BioRad ChemiDoc system and the image was processed using Image 
Lab 4.0 (Bio-Rad Laboratories). The used antibodies were: H2AX-pS139 (Biolegend, 
#613402), Rad21 (Santa Cruz, sc-54325), RPA32 (Merk Millipore, NA19L), Chk1 (Santa 
Cruz, sc-8408), Chk1-pS345 (Cell Signaling, #2348), p53-pS15 (Cell Signaling, #9286), 
Vinculin (Sigma, V9131), H3 (Abcam, Ab1791).  
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2.6 DNA combing 
Asynchronously growing cells were sequentially labeled with 25 μM IdU for 30 min 
followed by a brief wash with PBS and then 30 min incubation with 200 μM CldU in the 
cell culture medium. After labeling, cells were trypsinized, harvested and then embedded 
in agarose plugs until further analysis. The plugs were treated with proteinase K, then 
DNA was extracted and combed on silanized coverslips. DNA fibers were incubated first 
with a mouse anti-ssDNA antibody (Chemicon) followed by Alexa 546 coupled-
secondary antibody (Molecular Probes) staining. Incorporation of halogenated 
nucleotides was detected with specific antibodies (IdU: mouse anti-IdU/BrdU, Becton 
Dickinson; CldU: rat anti-CldU/BrdU, Abcam) and visualized with appropriate secondary 
antibodies. Images were acquired automatically with a spinning disk confocal 
microscope, and the individually labeled DNA molecules were manually measured with 
ImageJ. 
2.7 RNA extraction and analysis 
RNA was extracted using RNeasy total RNA extraction kit (Qiagen). Briefly cells were 
lysed by adding RLT buffer and the lysate was passed through a 20 gauge needle for 
several times. Then one volume of 70% ethanol was added to the collected lysate in a 1.5 
ml microtube and mixed well. The mixture was then transferred to an RNeasy spin 
column and centrifuged at ≥ 8000 xg for 15 minutes. The flow through was discarded and 
the column was washed with 350 µl of RW1 buffer. After a centrifuge step and 
discarding the flow through, DNase treatment was performed by adding 80 µl of DNaseI 
solution (10 µl of DNaseI stock + 70 µl of RDD buffer) to the column. After 15 minutes 
incubation, the column was washed first with 350 µl of RW1 buffer and then twice with 
500 µl of RPE buffer. Finally the flow through was discarded and the empty column was 
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centrifuged at full speed for 1 minute. RNA was eluted by adding 30-50 µl of RNase-free 
water into the column and centrifuge for 1 minute at 8000 xg. The extracted RNA was 
quantified using Nanodrop (ThermoFisher).  
Extracted and purified RNA was then used for cDNA synthesis with Superscript reverse 
transcriptase synthesis kit (invitrogen). 1 µg of RNA was combined with 1 µl of OligodT 
and 0.1 µl of Random primers, the final volume was reached to 30.5 µl by RNase-free 
water and then incubated at 70°C for 5 minutes. The samples were then quickly chilled at 
4°C for 5 minutes. Then, 19.5 µl of RT reaction (5 µl 25mM MgCl2 + 10 µl 5X reaction 
buffer + 2.5 µl 10 mM dNTP mix + 1 µl RNase inhibitor + 1 µl Reverse Transcriptase) 
was added to each sample. The reverse transcription protocol was then started by 5 
minutes incubation at 25°C and was followed by 60 minutes at 42°C. At the last step, RT 
enzyme was heat-inactivated by 15 minutes incubation at 70°C.  
Synthesized cDNA was used for subsequent Real-time RT-PCR. Quantitative RT-PCR 
reaction was performed using SYBR PCR master mix (Applied Biosytems, 10 µl SYBR 
master mix, 4 µl of 4 µM primer mix, 6 µl cDNA) in a BioRad CFX96 system. The data 
was analyzed using the 2 –ΔΔCt method. The primers used in real-time PCR are listed in 
table 1. 
For RNA-seq, total RNA was purified using QIAzol reagent (QIAGEN). DNase 
treatment was then performed with RNase-free DNase (QIAGEN). 5 ug of purified RNA 
was first treated with Ribozero rRNA removal kit (Illumine) and then precipitated with 
ethanol. RNA quality and removal of rRNA were checked with the Agilent 2100 
Bioanalyser (Agilent Technologies). Libraries for RNA-seq were then prepared with the 
TruSeq RNA Sample Prep Kit v2 (Illumine) following the manufacturer instruction.  
 
 
 53 
 
Table 2.1 List of primers and the sequences used in this study 
PRIMER NAME SEQUENCE (5’→ 3’) 
Rplpo-F 
Rplpo-R 
Rad21-F 
Rad21-R 
Nipbl-F 
Nipbl-R 
Smc3-F 
Smc3-R 
SRSF3-F 
SRSF3-R 
Ccd12-F 
Cdk12-R 
Cyclin K-F 
Cyclin K-R 
Cdk13-F 
Cdk13-R 
Fancd2-F 
Fancd2-R 
ATR exon9/10-F 
ATR exon9/10-R 
ATR exon10-F 
ATR exon10-R 
 
TTCATTGTGGGAGCAGAC 
CAGCAGTTTCTCCAGAGC 
ATTGACCCAGAGCCTGTGAT 
GGGGAAGCTCTACAGGTGGT 
AAAGGGAGCGCTTCTCAAA 
CAGCCTCCTGTGGGTAAGAA 
CCGTGCTTTCACTATGGACTG 
CAAGTCGAGACTTCCTTGTGTC 
GCAGTCCGAGAGCTAGATGG 
TTCACCATTCGACAGTTCCA 
AGAAGGAACCTATGGCCAAGTA 
TCTCACCTTCTTCAGAGCCACT 
CACCCTCACAACTTGAAGGAC 
CCAGTTGCCAGGGTATCATAG 
CCATGAAACCAAAGAAGCAA 
ACTAGGATCCAAGGCAAGCA 
AACTTGGAGGAGATTGATGGTC 
CGCTCTTTAGCAGACATGGA 
CTGCAGAGCTCCCATGAAG 
GACAATGTCAGAATCATCTTTGACT 
CTCTTCACGGCATGTTTTATTCTG 
TGGCTTTCAAGTTCCTACAGAAG 
 
 
2.8 Native isolation of proteins on nascent DNA (iPOND) 
Native iPOND was performed according to the protocol published by Leung et al. (Leung 
et al., 2013). Exponentially growing cells (50 × 10
6
 cells) were labeled with EdU (final 
concentration 10 uM) for 10 minutes. For thymidine chase, the EdU-containing medium 
was discarded, cells were rinsed with 37°C and CO2 equilibrated medium to remove 
residual EdU and then the medium containing 10 uM thymidine was added to the cells. 
Cells were then incubated at 37°C in the incubator for 1 hour. EdU pulse or thymidine 
chase was stopped by discarding EdU/thymidine containing media and ice-cold nuclei 
extraction buffer (20 mM Hepes pH 7.2, 50 mM NaCl, 3 mM MgCl2, 300 mM sucrose 
and 0.5% NP40) was immediately added to the monolayer cells in the dish. After 15 
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minutes incubation, cells were collected using cell scraper and then spun down for 10 
minutes at 2500 ×g. After two washes with ice-cold PBS, the cell pellet was resuspended 
in 5 ml of Click reaction mix (25 uM biotin-azide, 10 mM (+)-sodium L-ascorbate, 2 
mMCuSO4 in PBS, the negative control had DMSO instead of biotin-azide) and the 
samples were rotated at 4°C for 1 hour. The cells were then spun down for 10 minutes at 
2500 ×g at 4°C. The click reaction mix was discarded and after a washing step with PBS, 
the cell pellet was resuspended in 500 ul of lysis buffer B1 (25 mM NaCl, 2 mM EDTA, 
50 mM Tris-HCl pH 8.0, 1% NP40 plus protease and phosphatase inhibitors). After 15 
minutes incubation on ice, the lysate was sonicated for 10 seconds on ice. The samples 
were then centrifuged at max speed for 10 minutes at 4°C and the supernatants were 
discarded. The steps of lysis, sonication and centrifuge were repeated twice to remove 
soluble proteins and other non-chromatin proteins. After the second Centrifugation, the 
cell pellet was resuspended in 500 µl of lysis buffer and the samples were sonicated 10 
times each step 10 seconds with 10 seconds interval on ice. After centrifugation at max 
speed, the supernatant was transferred to a new eppendorf tube and an equal volume (500 
µl) of lysis buffer B2 (150 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl pH 8.0, 0.5% NP40 
plus protease and phosphatase inhibitors) was added to the samples. At this step, an 
appropriate aliquot of cell lysate was preserved as an input. The samples were then 
incubated overnight with streptavidin-coated dynabeads (invitrogen) on a rotating wheel, 
at 4°C. The following day, the dynabeads were collected using magnetic stand and the 
beads were washed four times with B2 buffer. Finally after a quick centrifuge (960 ×g, 3 
minutes) the residual B2 buffer was discarded and the beads were resuspended in 20 ul of 
5× Laemmli buffer. The iPOND together with input samples were boiled at 95°C for 15 
minutes and then run into the gel. 
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2.9 Chromatin Immunoprecipitation (ChIP) and DNA-RNA 
Immunoprecipitation (DRIP) 
First cells were fixed by adding 37% formaldehyde to the medium of tissue culture plate 
to a final concentration of 1% for 10 minutes. Next the cross linking was quenched by 
adding 2.5 M Glycine diluted to a final concentration of 125 mM while the plates were 
slowly shaking. After 5 minutes, the cells were rinsed three times with PBS and then 
scraped off the plates and spun down in a falcon tube. The pellet of ~ 10
8
 cells was then 
resuspended in 5 ml of cell membrane lysis buffer 1 (50 mM Hepes-KOH pH 7.5, 140 
mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100) containing 
protease and phosphatase inhibitors. After 10 minutes of incubation on ice, the lysate was 
centrifuged and the pellet was resuspended in 5 ml of lysis buffer 2 ( 10 mM Tris-HCl pH 
8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) supplemented with protease and 
phosphatase inhibitor while gently rocking for 10 minutes at room temperature. Nuclei 
were collected by centrifugation and the nuclear pellet was resuspended in 3 ml of nuclei 
lysis buffer 3 (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Na-
Deoxycholate, 2.5% N-lauroylsarcosine and protease and phosphatase inhibitor mixture). 
The suspension was then sonicated 7 cycles (30-seconds pulses followed by 30-seconds 
rest periods) using a Branson 450 CE sonicator (20% sonication amplitude, 6.4 mm probe 
diameter) on ice to shear chromatin to an average length of about 300-1000 bp. After that, 
300 µl of 10% Trition-X 100 was added to the sonicated lysate and chromatin was split to 
two 1.5-ml microcentrifuge tubes and was spun down at maximum speed to pellet the 
debris. The supernatant was aliquoted to the new microcentrifuge tubes. Dynabeads 
protein G (100 µl, invitrogen) that were washed and pre-blocked with PBS + 0.5% BSA, 
were incubated with 10 µg of the antibody, overnight at 4°C on a rotating wheel. Next 
day the beads were washed three times with 1 ml of blocking solution and then 100 µl of 
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resuspended beads in blocking solution was added to the cell lysates and rotated in a 
rotating wheel, overnight at 4°C. The day after, the beads were collected using a magnet 
and washed six times with pre-chilled wash buffer (50 mM Hepes-KOH pH 7.6, 500 mM 
LiCl, 1 mM EDTA, 10% NP-40 and 7% Na-Deoxycholate) and once with 1 ml of TE 
containing 50 mM NaCl. The residual buffer was removed by spinning down the beads at 
960 xg for 3 minutes and the beads were resuspended in 150 µl of elution buffer (TE + 
2% SDS) and incubated at 65°C for overnight. As the input, 1% of sheared chromatin was 
eluted in a same manner. Next day, the beads were spun down at maximum speed for 1 
minute and the supernatant was transferred to a new tube. The DNA was purified using 
Qiaquick kit (Qiagen) according to the instructions, quantified using Qubit
®
 dsDNA HS 
assay kit and further analyzed by real-time PCR. 2-10 ng of ChIP DNA was prepared for 
Illumina Genome Analyzer sequencing with TruSeq ChIP Sample Prep Kit (Illumina). 
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3 Results  
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3.1  Setting the siRNA screen 
3.1.1 Choosing an appropriate Myc-overexpressing cellular model 
To identify regulators of the Myc-induced DNA damage response (DDR) we performed a 
high-throughput automated siRNA screen based on the quantitative detection of DDR at 
single cell level.  
To set up the screen, we took advantage of a conditional Myc-overexpressing cellular 
system in which Myc is fused to the Estrogen Receptor (ER). This system has the 
advantage to allow a quick transcriptional-independent activation of Myc upon 4-
hydroxy-tamoxifen (OHT) treatment. In order to find a proper cellular model where Myc 
induced-DDR is robust enough to be detected by the immunostaining assay, we tested 
human osteosarcoma U2OS cell line and 3T9 immortal mouse embryonic fibroblast 
(MEF) cell infected with MycER construct. We also examined the primary embryonic 
fibroblast MycER-overexpressing cells that were derived from a knock-in mouse (homo- 
and heterozygous) where the MycER cDNA was inserted in the ROSA26 locus, under the 
control of R26 promoter (termed R26-MycER MEF). These cells were treated with OHT 
for 48 hours and Myc-induced DDR was measured by western blot analysis of ϒH2AX, a 
DNA damage marker (Figure 3.1). 
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Figure 3.1. Western blot analysis of ϒH2AX in stably MycER-
overexpressing cells 
U2OS-MycER, NIH/3T3-MycER immortalized MEF cells and clones (#10, #14) 
and R26-MycER primary MEF cells (hetero- and homozygous) were cultured. 
Myc overexpression was induced by adding OHT (400nM) to the culture 
medium. Ethanol was used as solvent control. After 48 hours, OHT-treated and 
ethanol-treated cells were harvested and subjected to ϒH2AX western blotting. 
Vinculin was used as a loading control (pbpMycER: pbabe-puroMycER, 
pBBMycER:pbabe-bleoMycER). 
Based on the robustness of the ϒH2AX signal, homozygous R26-MycER MEF cells were 
chosen for the screen. To ensure the consistency of the cells during the entire screening 
process, two immortalized clones were generated from two independent preparations of 
primary MEF cells (named Bz1 and Bz5) by using the 3T3 protocol (Figure 3.2A). 
Because Myc-induced DDR is known to engage the p53 pathway (Eischen et al., 1999, 
Zindy et al., 1998)  we checked p53 status of the immortalized lines by Sanger 
sequencing. Sequencing of the p53 gene revealed a homozygous point mutation (K129T) 
in Bz5 line, while the p53 gene was wild-type in Bz1 cell line. Consistent with the 
sequencing result, western blot analysis in Bz1 line showed that p53 protein is stabilized 
as a result of Myc activation compared to negligible level of the protein in control cells. 
In contrast, Bz5 line appeared to have a robust accumulation of the p53 protein 
independently of Myc activation, implying that p53 -most likely due to the loss of 
function nature of the mutation- is stabilized (Figure 3.2B). In addition, the p53-mutated 
cell line (Bz5) unlike the p53-WT line that was diploid, showed a polyploid FACS profile 
characterized by 4n and 8n peaks (Figure 3.2C). As p53 mutation and polyploidy may 
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affect and bias the result of our screen, we decided to carry out the RNAi screen with the 
Bz1 R26-MycER MEF line which is p53-WT and diploid.  
 
 
Figure 3.2. Generating and characterization of immortalized cells from 
R26-MycER primary MEFs 
Two independent preparations of primary MEF cells (Bz1 and Bz5) were 
passaged on a 3T3 protocol until the immortalized cells were established. (A) 
Growth curve of Bz1 and Bz5 MEF cells during continuous passages in culture 
in normal oxygen condition (20%). Under this condition many of primary MEFs 
undergo senescence, however some may acquire mutations and become 
immortal. Blue and red curves show the growth of Bz1 and Bz5 R26-MycER 
MEF cells respectively. (B) Western blot analysis of p53 (top panel) and vinculin 
(bottom panel) in Bz1 and Bz5 immortal MEF clones. (C) FACS profile of 
propidium-iodide-stained cells. Immortalized Bz1 line showed diploid DNA 
content profile whereas Bz5 clone displayed discrete 4n and 8n peaks (freshly 
isolated cells from mouse thymus were used as a control of diploid cells). 
 
A B 
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3.1.2 Establishing ϒH2AX immunofluorescence assay for quantitative detection of  
the Myc-induced DNA damage response 
The readout of the RNAi screen was based on immunofluorescence detection of ϒH2AX. 
For this reason, first the DNA damage induced by Myc in Bz1 R26-MycER MEF cell line 
was evaluated by ϒH2AX immunostaining. Western blot analysis of Myc-activated cells 
showed a progressive enhancement in H2AX phosphorylation up to 48 hours of Myc 
activation (Figure 3.3). Consistent with ϒH2AX western blot analysis, Myc 
overexpression caused a marked increase in the number of nuclear ϒH2AX foci 
(speckles) detected by immunofluorescence (Figure 3.4A). Based on the robustness of the 
Myc-induced DDR at 48 hours post OHT treatment, this time was chosen as the endpoint 
of the screen.  
 
Figure 3.3. Western blot analysis for detection of DDR activation in R26-
MycER MEF cell line upon Myc activation and Chk1 inhibition 
Bz1 R26-MycER cells were treated with OHT or ethanol and with UCN-01 or 
DMSO and then were harvested 24 and 48 hours post treatment for measuring 
H2AX phosphorylation by western blotting. Vinculin was used as a loading 
control. The final concentration of OHT and UCN-01 was 400 nM and 10 µM 
respectively. 
To evaluate the dynamic range (signal to background ratio) of the immunofluorescence 
assay, a massive Myc-induced replicative stress was triggered in Bz1 R26-MycER MEF 
cell line by coupling Myc activation with UCN-01 treatment, a Chk1 inhibitor previously 
shown to provoke cytotoxic DDR in Myc-overexpressing cells. This treatment mimics the 
situation of targeting a tumor maintenance gene (such as Chk1) in cells with high levels 
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of Myc (Murga et al., 2011), thus causing a robust DNA damage. Indeed treating Myc-
overexpressing Bz1 MEF line with Chk1 inhibitor (UCN-01) led to a strong enhancement 
of ϒH2AX signal, as detected by western blotting (Figure 3.3). Immunostaining of the 
cells for ϒH2AX, displayed mostly a uniform staining in the nuclei (referred to pan-
nuclear signal, Figure 3.4B). Given the broader dynamic range of pan-nuclear signal 
compared to the ϒH2AX foci, we used pan-nuclear signal as a quantitative assessment of 
DDR in our screen. 
 
 
Figure 3.4. Immunofluorescence detection of ϒH2AX foci and pan-nuclear 
signal in Bz1 R26-MycER MEF cell line 
Cells were treated with OHT or ethanol for 48 hours. UCN-01 or DMSO was 
added the last 3 or 6 hours of treatment. After fixation, the cells were stained 
with ϒH2AX (red) and counterstained with DAPI (blue). (A) Representations of 
immunofluorescence staining for ϒH2AX in untreated cells (control), OHT, 
UCN-01 and double treated cells. (B) Quantification of ϒH2AX signal. Left plot 
shows the percentage of the pan-nuclear stained cells. Median values are depicted 
for each treatment. Right plot shows the total intensity of the ϒH2AX signal 
(speckles and pan-nuclear staining) per nucleus. a.u. arbitrary units.  Final 
concentration for OHT was 400 nM and for UCN-01 was 10 µM. (The analysis 
was done by Dr. Fernanda Ricci in IIT screening unit).    
 
A 
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3.1.3 Optimization of siRNA transfection  
To set the siRNA transfection conditions in Bz1 R26-MycER MEF cell line, we tested 
different cell transfection reagents and different cell densities to find the optimal 
transfection condition with the highest transfection efficiency and the lowest cell toxicity. 
To this intent, different concentration of two widely used siRNA transfection reagents 
(Lipofectamine RNAiMAX and DharmaFECT1) were used to reverse transfect Bz1 R26-
MycER MEF cell line at three different cell densities in a 96-well plate. The transfection 
efficiency was assessed by measuring cell viability upon delivery of a toxic siRNA 
(siTOX) into the cells. Measured cell viability with MTT and CellTiter-Glo assays after 
48 hours of siRNA transfection showed a good performance of DharmaFECT1 
transfection reagent compared to Lipofectamine RNAiMAX (Figure 3.5). Among the 
tested conditions, 2000 cells with 0.2 µl of DharmaFECT1 yielded higher siRNA 
transfection efficiency (higher toxicity by siTOX) and low toxicity with no siRNA.  
 
Figure 3.5. Optimization of siRNA transfection in Bz1 R26-MycER MEF 
in 96-well plate format 
Cells (at different densities: 2000, 3000 and 5000 per well) were reversed 
transfected with 2.5 pmol of a toxic siRNA (siTOX) or no siRNA using different 
amounts of the transfection reagents Lipofectamine RNAiMAX and 
DharmaFECT1. Cell viability was measured 48 hours post transfection by the 
colorimetric MTT assay. Relative absorbance normalized to the mean absorbance 
of untransfected cells (no siRNA, no lipid) is presented. The experiment was 
repeated another time with comparable results. Assays were performed in 
triplicates. No si: no siRNA, L: lipid. 
 64 
 
The transfection conditions set in 96-well format, were further scaled down and re-tested 
in a 384-well plate. To do this, first the optimal cell density in 384-well format was 
determined by seeding different cell numbers and monitoring the cell growth over time 
(Figure 3.6A). We chose to seed 800 cells per well of 384-well plate since at this cell 
density cells were growing exponentially till 48 hours, which was the endpoint of the 
siRNA screen. The selected cell density was then used for testing different volumes of 
DharmaFECT1 reagent per well. Similarly to the set up experiment done in 96-well plate, 
we used siTOX for monitoring cell viability and assessing the transfection efficiency. 
Comparing the results, we chose the volume of transfection reagent (0.15 µl per well) that 
resulted in higher toxicity by siTOX and low toxicity by a pool of non-targeting siRNAs 
(Figure 3.6). 
    
Figure 3.6. Assessing the optimal siRNA transfection condition in 384-well 
plate format 
First, the optimal initial cell density was determined by seeding Bz1 R26-MycER 
MEF cell line at different cell densities in a 384-well plate and monitoring the 
cell growth over time. Once identified, the optimal cell density was used to set up 
the volume of the DharmaFECT1 transfection reagent. (A) Growth rate of Bz1 
R26-MycER MEF line measured by CellTiter-Glo viability assay. (B) Viability 
reduction of siRNA-transfected cells after 48 hours measured by CellTiter-Glo. 
siTOX (blue bars) was used to assess the transfection efficiency while non-
targeting siRNA pool (red bars) and lipid only (green bars) were used as the 
negative controls. The initial cell density was 800 cells per well. The experiment 
was repeated another time with a comparable results. (The data was generated by 
Dr. Michela Mattioli in IIT screening unit). 
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3.1.4 Selection of appropriate controls for the siRNA screen 
Like all the assays, for RNAi screen several negative and positive controls were needed. 
For the negative control, we tested a number of neutral siRNAs that do not target any 
transcript in murine cells (siRNAs against GFP, Renilla luciferase and non-targeting 
siRNA pool #2, Dharmacon, Thermo Scientific). Among those, the siRNA against 
Renilla luciferase (siRluc) served as the best negative control in terms of low toxicity and 
low impact on the basal ϒH2AX in the cells, giving results that were comparable with 
untransfected cells (data not shown). To ascertain the siRNA transfection efficiency in 
our screen, we took advantage of the siRNAs targeting essential genes like Plk1 and 
Kif11 that upon delivery, due to prolonged mitotic arrest, cause cell death in transfected 
cells.  
In addition to these transfection controls, we also needed a number of positive controls 
for Myc-induced DDR and for synthetic lethality. Despite the fact that UCN-01 treatment 
synergized with Myc in inducing DNA damage and eventually led to cell death, we 
observed that siRNA against Chk1 was not potent in inducing synthetic lethality and in 
increasing H2AX phosphorylation. As Chk1 is also a Myc target gene, we observed an 
up-regulation of Chk1 mRNA level in siChk1-transfected cells upon Myc activation 
compared to Chk1-depleted cells with endogenous level of Myc (Figure 3.7A). In line 
with the RT-qPCR results, the ϒH2AX western blot analysis in Bz1 R26-MycER MEF 
line showed no synergy between Myc overexpression and Chk1 depletion (Figure 3.7B).  
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Figure 3.7. Chk1 depletion in Bz1 R26-MycER MEF line by means of 
siRNA 
Bz1 R26-MycER line was transfected with siChk1 or a non-targeting siRNA 
(siCtrl) and was treated with OHT or ethanol at the same time. After 48 hours, 
cells were harvested for RT-qPCR and western blot analyses. (A) RT-qPCR 
analysis of Chk1 mRNA expression level upon Myc activation in siChk1-
transfected cells compared to control cells. mRNA expression level was 
normalized with a housekeeper gene (RPLPO) and is plotted relative to the 
siCtrl-transfected cells. Error bars show the standard deviation. (B) Western blot 
analysis of Chk1 and ϒH2AX in cells. Vinculin was used as a loading control. 
The experiment was done once. siCtrl: control siRNA, siChk1: siRNA against 
Chk1. 
The fact that Chk1 depletion by siRNA was not effective in inducing Myc-induced DDR, 
because of the positive regulation of Myc on the Chk1 gene, led us to examine a number 
of other genes whose knock-down previously shown to induced DDR and cell death 
selectively in Myc-overexpressing cells (Toyoshima et al., 2012). Among the tested 
genes, we noticed that Rad21 silencing led to a marked increase in phosphorylation of 
H2AX upon Myc activation (Figure 3.8A). Furthermore, Rad21 knock-down caused a 
significant reduction in the number of Myc-overexpressing cells compared to control cells 
with endogenous level of Myc (Figure 3.8B). Therefore Rad21 was selected as a positive 
control for either Myc-induced DDR and for synthetic lethality. 
A B 
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Figure 3.8. Immunofluorescence analysis of Myc-induced DDR in Bz1 
R26-MycER MEF line transfected with a number of previously-published 
Myc-synthetic lethal candidates 
Cells were transfected individually with siRNAs targeting Chk1, ATR, Rad17, 
Rad21, Wrn and Rluc and simultaneously were treated with OHT or ethanol. 
After 48 hours, cells were fixed and stained for ϒH2AX and DAPI. (A) 
Quantification of the percentage of ϒH2AX pan-stained nuclei in the transfected 
cells. The experiment was done manually in a 96-well plate. (B) Quantification 
of the number of nuclei and the percentage of ϒH2AX pan-positive nuclei in 
siRad21-transfected cells in comparison with the control cells in the presence or 
absence of OHT. siRNA transfection was performed automated in a 384-well 
plate. The assays were performed in triplicates. (Data was produced by IIT 
screening unit).  
3.2 A high-throughput siRNA screen for identification of modulators of 
Myc-induced DDR 
The RNAi screen was carried out in Bz1 R26-MycER MEF line in two conditions: (i) 
OHT- and (ii) ethanol-treated (high and normal Myc level respectively). We used a 
library that targeted around 1400 druggable genes from Dharmacon, arrayed in five 384-
A 
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well format plates, each well containing a pool of four individual siRNAs targeting a 
same gene. Forty-eight hours post siRNA transfection and OHT/ethanol treatment, cells 
were fixed and then stained with ϒH2AX antibody to measure the DNA damage 
response, and counterstained with DAPI to estimate the cell viability. Images were 
acquired using Olympus ScanR microscope for further analysis. Having three technical 
replicates for each condition (normal Myc and high Myc level) enabled us to perform 
statistical testing of the obtained results. As mentioned before, besides having negative 
control, siRNA against Renilla luciferase (siRluc), we chose siRad21 that was shown to 
increase DNA damage and lead to synthetic lethality in Myc-overexpressing cells, as a 
positive control for the assay. 
We assessed cell viability based on the number of DAPI-stained nuclei to identify genes 
whose depletion caused differential viability in Myc-overexpressing cells (Myc-OE) 
compared with the control cells (Myc-N). To do so, first the viability data of each well in 
a given plate was normalized to the median of the viability in siRluc-transfected cells 
(negative control) of that plate in order to correct inter-plate and inter-day variability. 
Taken the normalized viability, we then calculated the viability ratio of Myc-OE cells 
over Myc-N cells. Applying a stringent threshold of Z score of ≤ -2 on viability ratio of 
Myc-OE over Myc-N cells enabled us to identify the potential Myc synthetic lethal (Myc-
SL) hits. This analysis revealed 51 high confidence hits. We also defined a class of low 
confidence hits (45 hits) by using a less stringent Z score ≤ -1.5 and the viability ratio < 
0.7 (Figure 3.9A).  
To identify negative regulators of Myc-induced DDR (DDR-up hits), the enhancement in 
the background-corrected intensity of ϒH2AX in Myc-OE cells compared to control 
cells, was analyzed with four different methods, all based on MAD Z score in a pilot 
experiment (with approximately 280 genes). Evaluating these methods, we obtained a 
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good overlap between the hits coming from different methods. We then chose “difference 
in the percentage of ϒH2AX pan-positive nuclei” as a standard method for analyzing the 
entire screen. Applying this method we found 58 candidates whose knock-down 
significantly increased ϒH2AX signal in Myc-OE cells (Figure 3.9B). Furthermore, using 
a ϒH2AX-intensity threshold according to the negative (siRluc) and positive (siRad21) 
replicates in a given plate, we identified additional 59 candidates in this group that caused 
elevated ϒH2AX (Figure 3.9D). Quantification of ϒH2AX intensity in Myc-SL hits also 
showed a higher signal in a number of the cases (Figure 3.9C), whether this is the cause 
or the consequence of the synthetic lethality is an interesting issue to be addressed.  
Although the screen was aimed mainly on identification of negative regulators of Myc-
induced DDR, we were also able to identify two other groups of hits: (i) a group of 25 
hits (termed synthetic viable hits) which showed increased viability compared to negative 
control (siRluc) in Myc-overexpressing cells (normalized viability ratio of Myc-OE/Myc-
N ≥ 1.25,Figure 3.9E) and (ii) a group composed of 37 candidates that showed reduced 
ϒH2AX in OHT-treated cells compared to control cells (Percentage ϒH2AX pan-positive 
nuclei (OHT - EtOH) <0, referred to DDR-down hits, Figure 3.9D). Interestingly ATM 
was among the synthetic viable (SV) hits whose depletion increased the number of Myc-
overexpressing cells. This observation was in consistent with the tumor suppressive role 
of ATM in Myc-driven tumors, most likely by regulating p53-mediated Myc-induced 
apoptosis (Pusapati et al., 2006). Moreover, we also found some shared hits between two 
SV and DDR-down groups (Figure 3.9E). One possible explanation could be that those 
hits which reduced DNA damage may exert their function by blocking Myc-induced 
apoptosis thus increasing cell viability. Also, the synthetic viability could be simply a 
consequence of reduced DDR in these cells.  
 70 
 
 
Figure 3.9. Summary of siRNA screen and the identified groups of hits (see 
figure legend next page) 
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 (A, B, C) Scatter plots of the R26-MycER cell line (OHT/EtOH-treated) 
transfected with single siRNAs depicted as blue cross. (A) The normalized 
viability in OHT-teated (Y-axis) and ethanol-treated (X-axis) cells. Potential 
synthetic lethality hits are shown with red stars. (B) Percentage of ϒH2AX pan-
positive cells in OHT-treated cells compared to ethanol-treated cells. Potential 
DDR-up hits are shown as green stars. (C) DDR-up and SL hit distribution as a 
function of the percentage of ϒH2AX pan-positive nuclei is delineated. (D, E) 
Representation of DDR (up panel) and viability (low panel) hits in a given 
library: (D) difference in the percentage of ϒH2AX positive cells between OHT- 
and ethanol-treated cells was shown for each single siRNA. A ϒH2AX-based 
threshold (blue line) was set to identify DDR-up hits. Blue square shows DDR-
down hits; (E) viability ratio (OHT/EtOH) of the same plate. Red and blue lines 
were set to discriminate synthetic lethal (SL) and synthetic viable (SV) hits 
respectively. (F) Venn diagram showing the overlap between hits. SL: synthetic 
lethality, SV: synthetic viability, EtOH: ethanol. 
3.3  Secondary screen for verification of the initial hits 
False positivity may happen in every RNAi screen due to the off-target effect of siRNAs, 
for this reason we further validated our primary hits with a secondary screen using 
different siRNAs. The majority of primary hits were screened by Mission esiRNAs 
(Sigma). Each esiRNA is a pool of siRNAs resulting from endoribonuclease cleavage of 
long double strand RNA. As the starting material in esiRNA preparation is cDNA, these 
silencers are guaranteed to effectively target a specific real gene with lower off-target 
effect than single or pooled siRNAs. For the minority of the primary hits for which a 
targeting esiRNA was not available, three different individual silencer siRNAs (Ambion) 
were used in the secondary screen. Since for some hits, in the primary screen, the 
synthetic lethality was accompanied with ϒH2AX enhancement, it was not possible to 
discriminate if the synthetic lethality is the cause or the consequence of the increased 
ϒH2AX. Because of this reason, the synthetic lethal and DDR-up hits from the secondary 
screen were all classified as “positive hits” regardless whether they were called as 
synthetic lethal or DDR-up previously in the primary screen. With this criterion, overall 
43 out of 201 tested genes from esiRNA custom library were called as positive hits in 
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both primary and secondary screens. Among Ambion siRNA custom library, 7 out of 74 
genes (with at least two out of three single siRNA called as positive) were detected to 
cause synthetic lethality and/or to increase ϒH2AX in both screens. In addition, among 
the initial identified SV and DDR-down hits we verified 3 hits by the secondary screen. 
One possible reason for the low rate of hit validation in the SV/DDR-down class could be 
the lower dynamic range of the signal in this group, which reduced our confidence in 
calling the SV and DDR-down hits. The summary of the number of tested genes, initial 
positive hits and the validated hits is shown in table 3.1. 
 
Table 3.1. Summary of number of tested genes and number of positive hits 
in the primary and secondary siRNA screen 
 
3.4  Bioinformatics and network analysis 
To biologically and functionally annotate the verified hits, we used PANTHER and David 
functional classification tools. PANTHER showed the distribution of the hits in a variety 
of biological pathways including metabolism, cell cycle and cellular proliferation (Figure 
3.10). However, considering the distribution of all the tested genes (as background), the 
verified hits were not enriched in any particular process. DAVID functional analysis on 
hits also showed different clusters related to a variety of processes such as translation and 
protein synthesis, nuclear envelope and pore complex, intracellular transport, 
transcriptional regulation, mitochondrion and apoptosis.   
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Figure 3.10. Functional classification of the verified hits 
PANTHER representation of the biological process of all verified “positive hits” 
from screening.   
3.5  A biased primary screen against DDR genes 
In a complementary approach to the unbiased screen described above, we also chose a 
subset of genes that were linked to the maintenance of genome stability by previous study 
(Paulsen et al., 2009). With this aim, we selected around 1200 genes based on a previous 
genome-wide siRNA screen done in Cimprich lab (Paulsen et al., 2009). Whereas the aim 
of the RNAi screen by Paulsen and colleagues was to find the genes that affect genome 
stability in unperturbed cells (measured by ϒH2AX immunofluorescence), we were 
looking for genes whose knock-down would not largely affect the population but 
synergize with Myc-induced DDR to enhance ϒH2AX and/or to induce cell death. 
Therefore we chose mostly the genes from the Paulsen et al. hit list that moderately 
increased ϒH2AX without having a severe impact on the viability of the cells. Screening 
this collection of genes revealed 66 synthetic lethal hits and 39 DDR-up hits, among them 
23 were called in both groups. Interestingly, the SL and DDR-up hits showed a strong 
enrichment in the “nucleic acid binding” class and in particular the “RNA binding 
protein” class of proteins (Figure 3.11). By gene ontology analysis, these hits revealed to 
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have a role in mRNA processing and splicing. RNA post-transcriptional modification and 
splicing was also one of the enriched categories in Paulsen et al. study. The role of RNA 
processing machinery in preserving genome integrity is not very well known and has 
become the subject of some recent studies. Besides the RNA processing machinery, we 
also found eight hits as coding genes regulating protein degradation. Further validation is 
required to understand the role of these genes in Myc-overexpressing cells. 
 
Figure 3.11. Classification of the custom screen genes based on the encoded 
protein  
Classification of the total tested genes in custom library (A) and the positive (SL 
and DDR-up) hits (B) are shown. The subsets of the “nucleic acid binding” class 
in the hit category is further expanded in the pie chart. 
3.6  Validating the synthetic lethal interaction between Myc and 
SRSF3  
As mentioned above, the mRNA processing and splicing cluster was one of the most 
enriched group of positive hits arose from the custom siRNA screen. Therefore we 
decided to further validate one hit (SRSF3) from this group that was also among the 
positive hits of primary and secondary validation screens.  
We rationalized that if there is a dependency of Myc-overexpressing cells on the splicing 
factor SRSF3, we may obtain the same phenotype in other cell types as well. With this 
notion, we intended to validate the synthetic lethality between Myc overexpression and 
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SRSF3 depletion in U2OS cells overexpressing the conditional MycER fusion protein 
(hereafter termed U2OS-MycER). U2OS-MycER cells were reverse transfected with 
three different siRNAs against SRSF3 and a non-targeting siRNA (siControl) and, 
simultaneously, cells were treated with OHT (to activate Myc) or ethanol (as control). 
Cell viability assay at 48 hours post transfection/treatment showed a reduction in viability 
of the SRSF3-depleted cells overexpressing Myc compared to control cells or SRSF3-
silenced cells with normal Myc level (Figure 3.12). 
 
 
Figure 3.12. The effect of SRSF3 depletion on cell viability and cell 
proliferation of U2OS-MycER cells 
1.5×105 cells were reverse transfected independently with three different siRNAs 
against SRSF3 and a non-targeting siRNA (siCtrl) and were simultaneously 
treated with OHT or ethanol. At 48 hours post transfection cells were collected 
and counted by trypan blue. (A) percentage of dead cells and (B) total number of 
live cells are plotted. The experiment was performed once. 
Consistent with the screen data, western blot analysis of H2AX phosphorylation 
displayed a significant enhancement of ϒH2AX in Myc-overexpressing cells depleted of 
SRSF3 (Figure 3.13B). It should be noted that although high knock-down level of SRSF3 
(as achieved by siSRSF3 #2, Figure 3.13) had cytotoxic effect on cells and led to 
increased ϒH2AX even in the absence of Myc overexpression, the intermediate knock-
down level of SRSF3, at least up to 48 hours, did not affect largely the cell viability and 
the basal level of ϒH2AX in cells.   
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Figure 3.13. The effect of SRSF3 knock-down in U2OS-MycER cells 
Cells were transfected with three different siRNAs against SRSF3 and a control 
siRNA (siCtrl) and treated with OHT or ethanol at the same time. At 48 hours 
post transfection/treated cells were harvested for RT-qPCR and western blot 
analyses. (A) RT-qPCR analysis of SRSF3 expression level in transfected cells. 
Relative mRNA expression was measured using ΔCt method, normalized with a 
housekeeper gene (RPLPO) and is plotted relative to the control (siCtrl) cells. 
Values are the mean ± sd. (B) Western blot analysis for SRSF3 (upper panel), 
H2AX phosphorylation (middle panel) and vinculin (bottom panel) in transfected 
cells.  
We also analyzed the cell cycle profile of SRSF3-depleted cells by EdU incorporation. 
FACS analysis revealed a significant decline in EdU positive population in cells 
transfected with two different siRNA against SRSF3 (Figure 3.14). Myc overexpression 
in these cells caused a reduction in the percentage of G1 and an increase in the percentage 
of G2/M population.    
A 
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Figure 3.14. FACS analysis of EdU incorporation in U2OS-MycER cells 
transfected with three different siRNAs against SRSF3  
(See figure legend next page) 
At 48 hours post transfection and Myc activation, cells were pulsed with EdU for 
90 minutes, then harvested and subjected to EdU staining followed by propidium 
iodide staining. (A) Representative FACS profiles of cells transfected with siCtrl 
and a siRNA against SRSF3 (siSRSF3 #1) showing the EdU positive cells and 
the population of cells in G1 and G2/M phase of the cell cycle. (B) The 
percentage of cells in each phase of the cell cycle, as determined by EdU 
staining, is plotted. FACS analysis was performed once. 
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Moreover, FACS analysis on Myc-overexpressing siSRSF3-transfected cells stained with 
ϒH2AX and propidium iodide, displayed that ϒH2AX-positive cells were distributed in 
all cell cycle phases (Figure 3.15), suggesting that the accumulation of DNA damage in 
these cells may be the cause of synthetic lethality.  
 
 
 
Figure 3.15. Cell cycle distribution of ϒH2AX-positive cells upon SRSF3 
depletion and Myc activation (See figure legend next page) 
After 48 hours from transfection, cells were pulsed with EdU for 90 minutes, 
then collected, stained for EdU, ϒH2AX and propidium iodide and followed by 
FACS analysis. (A) FACS profiles of the transfected showing ϒH2AX-positive 
cells as a function of DNA content (B) Percentage of ϒH2AX-positive cells in 
each phase of the cell cycle is plotted. (C) Percentage of ϒH2AX-positive cells in 
different phase of the cell cycle normalized to the parental population is plotted. 
FACS analysis was performed once. 
A 
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3.7  Validating the Myc-Cdk12 synergy in enhancing DDR 
We also selected Cdk12, a DDR-up hit, for further validation in U2OS-MycER cells. Of 
note, Cdk12 depletion was also found in Toyoshima et al. study (Toyoshima et al., 2012) 
as a Myc synthetic lethal hit. Recently it has been shown that Cdk12 together with its 
cyclin partner, Cyclin K (CCNK), has a critical role in maintaining genomic stability, 
presumably via regulation of expression of DDR genes. Cdk12 or Cyclin K depletion was 
shown to sensitize cells to a variety of DNA damaging agents (Blazek et al., 2011, Liang 
et al., 2015). Therefore we decided to examine the effect of Cdk12, Cdk13 (the paralog of 
Cdk12) and Cyclin K depletion under Myc-induced replicative stress condition. Gene 
knock-down was achieved by transfecting U2OS-MycER cells with two individual 
siRNAs targeting Cdk12, Cdk13 and Cyclin K. Real-time RT-PCR analysis after 48 hours 
from transfection validated the knock-down of the corresponding genes (Figure 3.16). 
. 
 
 
Figure 3.16. Quantitative RT-PCR analysis of Cdk12, Cdk13 and CCNK 
expression level in siRNA-transfected cells 
Two different siRNAs were used for each gene silencing. Relative mRNA 
expression was measured using ΔCt method, normalized with a housekeeper 
gene (RPLPO) and is plotted relative to the control (siCtrl) cells. Values are the 
mean ± sd. 
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We then examined the cell viability and cell growth of Myc-activated or non-activated 
cells depleted of Cdk12, Cdk13 and Cyclin K. Indeed, cell viability was not largely 
affected in siCdk12-transfected cells (with endogenous or high level of Myc). In contrast, 
Myc-overexpressing cells depleted of Cdk13 and Cyclin K exhibited a significant higher 
level of dead cells and the cell proliferation was reduced in these cells, while siCdk13- or 
siCCNK-transfected cells with endogenous level of Myc just showed a slight increase in 
cell death (Figure 3.17).   
 
 
Figure 3.17. The effect of Cdk12, Cdk13 and Cyclin K depletion on cell 
viability and cell proliferation of U2OS-MycER cells 
1.5×105 cells were reverse transfected with two individual siRNAs (#1 and #2) 
against each gene. At 48 hours post transfection, cells were collected and counted 
by trypan blue. (A) Percentage of dead cells and (B) total number of live cells are 
plotted. The experiment was performed once. 
Since in our siRNA screen the depletion of Cdk12 in Myc-activated cells yielded a higher 
percentage of ϒH2AX-positive cells, we examined the level of H2AX phosphorylation in 
the transfected cells by western blot analysis. Cdk12 depletion by both siRNAs 
significantly increased ϒH2AX levels in Myc-overexpressing cells but not in cells 
possessing normal Myc level. Similarly, Cdk13 and Cyclin K depletion (dependent on the 
A B 
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siRNA) also synergized with Myc-activation to enhance H2AX phosphorylation (Figure 
3.18). 
 
Figure 3.18. Western blot analysis for H2AX phosphorylation in U2OS-
MycER cells transfected with siRNAs against Cdk12, Cdk13 and Cyclin K 
Two different individual siRNAs (#1 and #2) were used for gene knock-down. A 
non-targeting siRNA (siCtrl) was used as a control. Cells were treated with OHT 
or with ethanol at the same time of transfection, and harvested 48 hours post 
treatment. Vinculin was used as a loading control. Western blot analysis was 
performed twice with consistent results. 
The Cdk12/Cyclin K complex has been shown to regulate the expression of long and 
complex genes (such as DNA damage response genes) through phosphorylation of C-
terminal domain of RNA polymerase II (Blazek et al., 2011, Liang et al., 2015). 
Therefore, we sought to investigate the expression of some DDR genes that was shown to 
be deregulated upon CdK12/Cyclin K depletion in previous studies (Blazek et al., 2011, 
Liang et al., 2015). Myc-activated and non-activated cells depleted of Cdk12, Cdk13 and 
Cyclin K as well as siCtrl-transfected cells, were harvested at 48 hours post transfection 
and analyzed for expression of ATM, FANCD2 and ATR genes. To our surprise, 
quantitative RT-PCR of the tested DDR genes did not show any significant reduction in 
the mRNA level (Figure 3.19). Therefore, more thorough analysis is needed to investigate 
the possible role of Cdk12/Cyclin K in regulating DDR genes.   
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Figure 3.19. Quantitative RT-PCR analysis of ATM, FANCD2 and ATR 
expression level in Cdk12, Cdk13 and Cyclin K-silenced cells 
Two different siRNAs (#1 and #2) were used for each gene silencing. Primers for 
amplifying ATM and FANCD2 are either exon-exon spanning or intron-flanking. 
For ATR amplification, one intron-flanking primer pair (ATR exon9/10) and one 
intron-spanning primer pair (ATR exon10) were used. Relative mRNA 
expression was measured using ΔCt method, normalized with a housekeeper 
gene (RPLPO) and is plotted relative to the control (siCtrl) cells. Values are the 
mean ± sd. 
In summary, we validated synergistic effect of Myc-induced DDR with depletion of two 
hits from siRNA screen (Cdk12 and SRSF3) in U2OS-MycER cells. Further studies are 
needed for unraveling the mechanism behind these effects.  
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3.8  Validation of the synthetic lethal interaction linking the Myc 
oncogene to Rad21 depletion 
During the set-up of the RNAi screen, by comparing the identified hits with the positive 
control (siRad21) we saw very robust synthetic lethality and a remarkable enhancement 
of ϒH2AX in Rad21-depleted cells upon Myc activation. In addition, the fact that this 
synthetic lethality is observed in different cellular models (R26-MycER MEF, shown in 
figure 3.8, and NMuMG-MycER cells, data not shown) proposed a strong interaction 
between Myc and Rad21. As the mechanism of this synthetic lethal interaction has not 
been investigated, we sought to explore some underlying mechanisms that might account 
for this effect. 
3.8.1 Rad21-Myc synthetic lethality is subsequent to the accumulation of cytotoxic 
DNA damage 
To validate Myc-SL with Rad21 depletion we selected the human osteosarcoma cell line 
U2OS and generated a stable cell line with conditional Myc-estrogen receptor (ER) fusion 
protein (U2OS-MycER). These cells were then transfected with either a siRNA against 
human Rad21 (siRad21) or a non-targeting siRNA (siCtrl) as a negative control and 
simultaneously were treated with OHT, to activate Myc, or ethanol, as a control. Cell 
proliferation and cell death were monitored at 24, 48 and 72 hours post siRNA 
transfection/Myc activation. The growth curve of siRad21-transfected cells displayed a 
reduction in cellular growth compared to control cells (Figure 3.20A), while cell viability 
was not dramatically changed, suggesting a role for Rad21 in cell cycle progression and 
proliferation. Activation of Myc in Rad21-silenced cells showed a further decrease in cell 
growth which was mostly because of the cell death. These cells displayed a striking 
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reduction in cell number at 72 hours post siRad21 transfection/Myc activation that was 
concordant with robust cell death at this time (Figure 3.20B and 20C).  
 
 
Figure 3.20. The effect of Rad21 silencing on the cell growth of normal and 
Myc-overexpressing cells 
At time 0, U2OS-MycER cells were transfected with Rad21 siRNA (siRad21) or 
a non-targeting siRNA (siCtrl) and simultaneously treated with ethanol or OHT. 
The cells were counted at 24, 48 and 72 hours post transfection. (A) Growth 
curve of siRNA-transfected cells over a period of 3 days post transfection. (B) 
Percentages of the dead cells assessed by trypan blue staining. (C) Representative 
picture of transfected/treated cells after 72 hours. Comparable results were 
obtained in at least five independent experiments. siCtrl: control siRNA, 
siRad21: siRNA against Rad21, Myc-N: normal Myc level, Myc-OE: Myc 
overexpression, EtOH: ethanol. 
Previously in our siRNA screen Myc-Rad21 synthetic lethality was paralleled by an 
increase in the percentage of ϒH2AX positive cells, for this reason we examined H2AX 
phosphorylation in U2OS-MycER transfected cells over time. siRNA-transfected cells 
A B 
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were harvested at 24, 48 and 72 hours post transfection and analyzed by ϒH2AX western 
blotting (Figure 3.21A). Consistent with previous data, we observed a substantial increase 
of ϒH2AX in Rad21-depleted cells that were treated with OHT. The enhancement in 
H2AX phosphorylation was more evident starting from 48 hours post siRNA transfection 
and Myc overexpression, when there was no massive cell death in the population, 
implicating that the accumulation of DNA damage preceded by time and most likely 
account for the cytotoxic effect seen at later time points.  
 
 
Figure 3.21. Western blot analysis of U2OS-MycER transfected cells 
(A) U2OS-MycER cells were transfected with siRad21 or siCtrl and were treated 
with OHT or ethanol at the same time. Cells were harvested at 24, 48 and 72 
hours post transfection and analyzed for H2AX phosphorylation by western 
blotting. Vinculin used as a loading control. (B) Western blot analysis of Rad21 
(upper panel) and ϒH2AX (bottom panel) in U2OS-MycER cells transfected 
with siRad21 and harvested at the indicated times after transfection. siCtrl-
transfected cells at 48 hours post transfection were used as a control. Note that 
cells were not treated with OHT. Western blot analyses were repeated twice with 
comparable results. 
 
A 
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Therefore, we concluded that while Rad21 knock-down per se did not trigger DNA 
damage (up to 6 days after siRad21 transfection, Figure 3.21B), it synergized with Myc 
overexpression to induce DNA damage response. This notion was supported by ϒH2AX 
immunofluorescence staining. Cell staining at 48 hours post siRNA transfection displayed 
an increased ϒH2AX foci in siRad21-transfected Myc-activated cells compared to other 
experimental groups, whereas at the time of 72 hours most of these cells displayed 
apoptotic features with uniform ϒH2AX staining on the nuclei (Figure 3.22). 
 
Figure 3.22. ϒH2AX immunofluorescence in U2OS-MycER cells 
siCtrl- or siRad21-transfected cells treated with OHT or ethanol, were fixed at 48 
and 72 hours post transfection, stained with ϒH2AX (green) and counterstained 
with DAPI (blue). The nuclei are outlined by a red line in the enlarged images. 
ϒH2AX immunofluorescence was repeated twice with comparable results. 
3.8.2 Rad21 depletion does not sensitize cells to DNA damaging agents 
The cohesin complex has been shown to facilitate double strand break repair via 
homologous recombination, therefore it is conceivable that depletion of cohesion subunits 
under DNA damage condition -such as Myc-induced RS- might affect genome stability 
and cell survival. To understand the impact of Rad21 depletion on different DNA damage 
signaling pathways, we examined the sensitivity of Rad21-silenced cells to other types of 
DNA damage. For this purpose, first Rad21 was depleted in U2OS cells by the specific 
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siRNA and then Rad21-depleted and control cells were exposed to several different DNA 
damaging agents. Comparing Rad21-silenced cells with control cells, we did not see any 
further sensitivity in these cells when cells were irradiated with ionizing radiation (IR) or 
treated with DNA damagereplication stress inducing agents camptothecin (CPT) or 
Hydroxyurea (HU) (data not shown). We also measured the DNA damage response in 
these cells by western blot analysis of ϒH2AX (Figure 3.23). The enhancement of 
ϒH2AX in irradiated Rad21-depleted cells was comparable to irradiated control cells 
after 4 hours of recovery. In addition, the increased level of ϒH2AX was declined to a 
similar level in control and in Rad21-silenced cells at 24 hours after irradiation, 
suggesting that Rad21-depleted cells were able to sense and respond to DNA damage 
induced by IR. Furthermore, siRad21-transfected cells subjected to CPT or HU for 4 
hours, showed reduced H2AX phosphorylation compared to siCtrl-transfected cells 
treated with the same drug. This low level of ϒH2AX in CPT-treated cells increased with 
time and reached the same level as in siCtrl-transfected cells after 24 hours of treatment. 
Since CPT-mediated DNA damage is shown to be largely replication-dependent (Cliby et 
al., 2002), the lower ϒH2AX level in siRad21-transfected cells after 4 hours of treatment 
may refer to the lower percentage of cells in S-phase compared to siCtrl-transfected cells. 
The amount of ϒH2AX in Rad21-depleted cells after 24 hours treatment with HU was 
still lower than the control cells, which may be due to the role of HU in preventing S-
phase progression in cells. 
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Figure 3.23. Analysis of DNA damage response in siCtrl- and siRad21-
transfected cells upon exposure to different DNA damage agents 
U2OS cells were first transfected with siCtrl or siRad21 and at 48 hours post 
transfection cells were exposed to different DNA damaging agents. At the 
indicated times, the cells were harvested and subjected to western blot analysis 
for ϒH2AX (upper panel), Rad21 (middle panel) and vinculin (bottom panel). 
The dose of IR used was 10 Gy. The final concentration of the drugs was 1 µM 
for CPT and 2 mM for HU. The times indicated for IR irradiation are the 
recovery time after 10 Gy IR. For CPT and HU the incubation times with the 
drug are shown. The experiment was performed once. 
3.8.3 Myc overexpression in Rad21-depleted cells enforces DNA synthesis and 
provokes replicative stress  
Considering the direct role of Myc in promoting DNA synthesis and the fact that Rad21 
depletion was reported to slow down S-phase (Guillou et al., 2010), we asked whether 
Myc activation would alter the cell cycle distribution of Rad21-silenced cells. To address 
this question we determined the cell cycle profile of siCtrl- or siRad21-transfected U2OS-
MycER cells (with and without Myc activation) at 24, 48 and 72 hours post transfection. 
Cell cycle analysis of Rad21-depleted cells showed a progressive decrease in the 
percentage of S-phase and an increase in the G1 phase of the cell cycle over time (Figure 
3.24), confirming that Rad21 down-regulation affected S-phase entry in these cells. 
However, the population of S-phase cells in Rad21-silenced cells that were 
overexpressing Myc, was not significantly affected compared to control cells. 
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Figure 3.24. Cell cycle analysis of U2OS-MycER cells at different time post 
siRNA transfection 
U2OS-MycER cells were transfected with siCtrl or siRad21 and treated with 
OHT or ethanol. Cells were collected after 24, 48 and 72 hours of 
transfection/treatment and stained with propidium iodide (PI). (A) FACS profiles 
of PI-stained cells showing DNA content. (B) Percentage of cells in each phase 
of the cell cycle is plotted. Comparable results were obtained in at least three 
independent experiments. 
To measure DNA synthesis more precisely, we assessed the level of BrdU incorporation 
in Rad21-depleted cells and in relative controls, by BrdU pulse labeling of the cells at 48 
hours post siRNA transfection (siCtrl or siRad21) and Myc activation. FACS analysis 
showed a higher percentage of BrdU positive cells in Myc-overexpressing cells (57%) 
compared to control cells (47%). Moreover, Rad21-depleted cells showed a striking 
reduction in BrdU incorporation (18%) while the G1 population was remarkably 
A 
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increased (Figure 3.25). However, the BrdU positive population in Myc-overexpressing 
cells that were transfected with siRad21 just showed a slight reduction (35%) compared 
to siCtrl-transfected cells with normal Myc level (47%). Noteworthy, we also noticed a 
significant increase in G2/M phase of Rad21-depleted cells overexpressing Myc (Figure 
3.25B) that could be due to the activation of G2 checkpoint in these cells.  
 
 
Figure 3.25. FACS analysis of BrdU incorporation in U2OS-MycER 
transfected cells 
Cells were transfected with siCtrl and siRad21 and simultaneously were treated 
with OHT or ethanol. At 48 hours post transfection, cells were pulsed with BrdU 
for 30 minutes, then collected and subjected to BrdU staining followed by flow 
cytometry analysis. (A) FACS profiles depicting BrdU incorporated population 
in pink gates. The G1 and G2/M populations were shown in black gates. (B) The 
percentage of cells is each phase of the cell cycle as determined by BrdU staining 
is plotted. Values are the means from three independent replications. Error bars 
indicate standard deviation.  
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Taken together we hypothesized that while Rad21 depletion negatively affects DNA 
synthesis, ectopic activation of Myc is able to enforce the cells into S-phase. As Myc 
activation was performed simultaneously with siRad21 transfection, we wondered 
whether Myc prevents or whether it rescues the S-phase defect of Rad21-silenced cells. 
To address this question, Rad21 was first depleted in U2OS-MycER cells by using 
specific siRNA and 24 hours post transfection the transfected cells were synchronized in 
G2/M by Nocodazole treatment. The mitotic-arrested cells were then collected by mitotic 
shake off and released into the medium containing OHT (to activate Myc) or ethanol (as 
control) supplemented with BrdU. Quantification of BrdU-immunofluorescent cells over 
time after nocodazole release displayed a significant increase in the percentage of BrdU 
positive cells in Myc-overexpressing cells compared to cells with endogenous level of 
Myc (Figure 3.26). In addition there was a remarkable decrease in the percentage of BrdU 
positive cells that were transfected with siRad21. Interestingly, Myc overexpression in 
these cells led to a significant increase in the S-phase population measured by BrdU 
incorporation (Figure 3.26). This enhancement in the percentage of BrdU-positive cells 
was still lower than control cells suggesting that Myc is able to promote DNA synthesis 
in slow-growing Rad21-depleted cells and thus partially rescue the S-phase defect and the 
G1 arrest observed in these cells. 
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Figure 3.26. Immunofluorescence analysis of BrdU incorporation in 
U2OS-MycER cells released from nocodazole arrest 
siCtrl or siRad21-transfected cells, at 24 hours post transfection, were 
synchronized in G2/M phase by nocodazole treatment. Mitotic arrested cells 
were then collected and released into the medium containing OHT or ethanol and 
supplemented with BrdU. Cells were fixed at specified time points and stained 
with an anti-BrdU antibody. (A) Representative images of BrdU immunostaining 
in cells at 18 hours post release. (B) Quantification of the percentage of BrdU-
positive cells in 24 hours time frame post release. The experiment was performed 
once. Values are the mean ± sd of five field of view (magnification ×4) with total 
number of 1500 nuclei. 
Notably, BrdU immunofluorescence in Rad21–silenced cells in asynchronous population 
exhibited a large number of nuclei having very few dispersed BrdU spots (Figure 3.27A). 
This staining pattern is known to be typical of late S-phase cells, however sub-dividing S-
phase cells based on FACS profile to early, middle and late S-phase in siRad21-
transfected population yielded equal percentages in each sub-class, that was comparable 
with control cells. This led us think that Rad21-depleted cells may have defects in DNA 
replication. The dispersed BrdU foci were also present in siRad21-transfected cells 
A 
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overexpressing Myc, though the percentage was lower (Figure 3.27B), suggesting that 
Myc may rescue the replication defects in Rad21-depleted cells. Noteworthy, these cells 
also showed higher percentage of late S-phase and G2/M population. Therefore the nuclei 
with few BrdU foci, at least partly, could be the late S-phase cells.  
 
 
Figure 3.27. Immunofluorescence analysis of BrdU incorporation in 
asynchronous population of U2OS-MycER cells  
siCtrl- or siRad21-transfected cells, treated with OHT or ethanol, were fixed at 
48 hours post transfection and subjected to BrdU staining. (A) Representative 
images of BrdU immunofluorescence. Examples of nuclei having BrdU dispersed 
foci are depicted by arrowheads. (B) Quantification of the percentage of total 
BrdU-positive cells subdivided to pan, foci>10 and foci<10. The experiment was 
performed once. Values are mean ± sd of ten field of view (magnification ×40), 
with total number of 150 cells.   
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To investigate DNA replication kinetics and see if and how DNA replication is affected 
by Rad21-depletion and Myc-overexpression, we used DNA combing assay. U2OS-
MycER cells were transfected with siRad21 or siCtrl and treated with OHT or ethanol. 
After 48 hours from transfection and Myc activation, cells were sequentially pulsed-
labeled first with the thymidine analogue IdU for 30 minutes and then with CldU for 30 
minutes. After genomic DNA extraction, DNA fibers were prepared by molecular 
combing and newly synthesized DNA, labeled with IdU and CIdU, was detected by 
fluorescent antibodies. Fork speed was calculated by dividing the length of each 
fluorescent signal by the time of the pulse. Symmetry of replication fork progression was 
also analyzed considering the velocity of the left and right arms of replication fork of a 
given origin. The inter-origin distance that reflects the number of fired replication origins 
was also measured on individual DNA fibers.  
The DNA combing results displayed a higher fork progression rate in Rad21-depleted 
cells regardless of Myc overexpression (0.8 Kb/min in siCtrl and 1.2 Kb/min in siRad21) 
and a slightly higher inter-origin distance in Rad21-depleted cells (Figure 3.28A and 
Figure 3.28B). Notably, Rad21 silencing caused a dramatic increase in the percentage of 
unidirectional forks (20% in siCtrl and 45% in siRad21) revealing that a considerable 
fraction of replication forks was prematurely terminated (Figure 3.28C).  
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Figure 3.28. Analysis of DNA replication by DNA combing 
U2OS-MycER cells were transfected with siCtrl or siRad21 and treated with 
OHT or ethanol at the same time. At 48 hours post transfection cells were 
sequentially pulsed with IdU and CldU for 30 minutes and then collected for 
DNA combing. Fork rate values (A) and inter-origin distances (B) were shown in 
scatter plots. Horizontal lines and the numbers above the plots represent mean 
values for fork velocity and median for interorigin distance. (C) Quantification of 
the symmetry of fork progression. Forks were considered as symmetric if the 
difference between two replication forks were less than 30%. If the difference 
was more than 30%, fork was considered as asymmetric. Unidirectional forks 
were defined if only one replication fork departs from origin. (DNA combing 
was performed once and in collaboration with Dr. Aurora Cerutti and Dr. 
Fabrizio d'Adda di Fagagna). 
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Given the fact that Myc induction enforces DNA synthesis in Rad21-depleted cells, we 
hypothesized that the Myc-induced synthetic lethality in the absence of Rad21 could be 
originated by boosting the replicative stress in these cells. To investigate the presence of 
replication stress in these cells, we analyzed H2AX phosphorylation as cells traverse into 
the S-phase of the cell cycle. The experimental design is shown in figure 3.29A. Briefly, 
U2OS-MycER cells were transfected with siCtrl or siRad21 and after 24 hours of siRNA 
transfection, cells were subjected to two rounds of thymidine arrest. Excess of thymidine 
inhibits DNA synthesis and thus synchronizes cells in G1/S boundary. After the first 
synchronization, Rad21-silenced cells, as well as the control cells, were released into a 
medium containing either OHT or ethanol. EdU, an analogue of thymdine, was also given 
to the released cells to discriminate the S-phase cells. Cells were harvested 12 hours post 
release and analyzed by FACS. FACS analysis of EdU incorporation and H2AX 
phosphorylation showed a slight increase in ϒH2AX in the EdU-positive population of 
Rad21-depleted cells that were treated with OHT (Figure 3.29B). To monitor ϒH2AX 
enhancement that may happen in the S-phase of the next cell cycle, released cells from 
the first thymidine block were subjected to a second round of thymidine arrest. EdU was 
added as the cells were released into a fresh medium. These cells were then collected at 4, 
8 and 12 hours post release for FACS analysis. Cell staining using the antibodies reacting 
with ϒH2AX and EdU following fluorescence-activated cell sorting, exhibited 
progressive accumulation of ϒH2AX in the EdU-positive population of Myc-activated 
cells that were depleted of Rad21 compared to either Myc-activated cells or Rad21-
silenced cells. In contrast, neither thymidine-arrested cells nor the cells that did not 
incorporate EdU displayed ϒH2AX accumulation, suggesting that the synergy between 
Myc overexpression and Rad21 depletion in enhancing DDR is occurring mostly in S-
phase of the cell cycle and is more pronounced after long-term Myc activation.   
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Figure 3.29. FACS analysis of ϒH2AX and EdU in U2OS-MycER cells 
released from thymidine arrest 
Twenty-four hours post siRNA transfection, siCtrl- or siRad21-transfected cells 
were subjected to two rounds of thymidine arrest and release. Cells were treated 
with OHT or ethanol as they released from the first thymdine arrest and were 
kept in OHT- or ethanol-containing medium through the second arrest and 
release. EdU was added to the medium when the cells were released or when 
they were arrested by thymidine. Cells were collected at the indicated time (12 
hours after the first release - before the second release - 4, 8 and 12 hours after 
the second release), subjected to ϒH2AX and EdU staining and followed by 
FACS analysis. (A) Experimental design of double thymdine arrest is depicted. 
(B) Representative FACS profile of ϒH2AX and EdU staining in the released 
cells from the second thymidine arrest for 12 hours. (C) Quantification of 
ϒH2AX positive cells in EdU-positive and EdU-negative populations during 
thymidine arrest and release. The experiment was performed once and values are 
normalized to the population size and are relative to control sample (siCtrl).  
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We also analyzed RPA foci formation as a marker of single stranded DNA that can be 
generated by replication stress. Quantification of the number of RPA foci in 
asynchronous population of transfected cells, at 48 hours post transfection, showed an 
increase in DNA-bound RPA in Rad21-depleted cells in the presence of elevated Myc 
level (Figure 3.30). All together, these results led us to propose that Rad21-depleted cells 
undergo replicative stress upon Myc overexpression.  
 
    
Figure 3.30. Quantification of RPA foci in U2OS-MycER cells determined 
by immunofluorescence 
Cells were transfected with siCtrl or siRad21 and simultaneously treated with 
OHT or ethanol. Forty-eight hours post transfection/treatment, cells were pre-
extracted, then fixed and stained for RPA. Representative immunofluorescence 
images of RPA staining for the indicated treatment are shown under the graph. 
The experiment was repeated once. Each bar represents mean ± SEM. 
3.8.4 Rad21 is present in replication sites and may have a direct role in DNA 
replication 
Since the lack of Rad21 was shown to reduce DNA synthesis by several studies as well as 
the current study, we asked whether RAD21 protein has a direct function in DNA 
synthesis. Therefore we applied native iPOND technique to isolate the proteins on newly-
synthesized DNA and to see whether RAD21 is among the replication associated 
proteins. To this end, asynchronous U2OS cells were shortly pulsed with EdU (10 
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minutes), then harvested and lysed with the nuclear extraction buffer. After a step of 
adding biotin-azide to EdU (named click reaction), biotinylated chromatin was captured 
by streptavidin beads and western blot analysis was used to identify RAD21 protein. To 
distinguish the replication-associated proteins from the other chromatin bound proteins, a 
part of U2OS cells after EdU pulse was briefly washed with equilibrated media (37°C and 
5% CO2) and then chased with thymidine for an hour. Thymidine competes with residual 
EdU inside the cells to be incorporated into DNA and in this way the replication-
associated proteins travel far from the EdU incorporated region.  
Along with replisome component PCNA, native iPOND revealed an enrichment of 
RAD21 protein in EdU-pulsed sample, but not in the thymidine-chased sample or the 
sample that omits the biotin-azide during the click reaction (Figure. 3.31).  
 
Figure 3.31. Western blot analysis of the input and the captured proteins 
following native iPOND on U2OS-MycER cells  
U2OS-MycER cells were pulsed with EdU for 10 minutes and then harvested for 
iPOND. In thymidine chase sample, after EdU pulse, the medium was washed 
out and cells were incubated with thymidine-containing medium for 1 hour. In 
DMSO control, no biotin was added in the click reaction. Comparable results 
were obtained with two independent experiments. 
3.8.5 Myc overexpression induces phosphorylation of p53 and leads to G2/M arrest 
in Rad21-depleted cells 
Cell cycle analysis showed the majority of Myc-activated siRad21-transfected cells 
arrested in G2/M phase of the cell cycle (Figure 3.25), therefore we hypothesized that 
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accumulation of DNA damage during S-phase in these cells may lead to activation of G2 
checkpoint and eventually cell cycle arrest. To test this hypothesis, we sought for the 
different DDR-mediated modifications on the DNA damage response factors in Myc-
activated Rad21-silenced cells by western blotting.  
 
Figure 3.32. Western blot analysis for different DDR marker in U2OS-
MycER cells  
U2OS-MycER cells were transfected with siCtrl or siRad21 and simultaneously 
were treated with OHT or ethanol. Cells were harvested at 48 hours post 
transfection and subjected to western blot analysis. Comparable results were 
obtained with two independent experiments. 
Western blot analysis for phospho-Chk1 showed a slight increase in the phospho-Chk1 
band in Myc-overexpressing cells, however Rad21-depleted cells with normal or high 
level of Myc did not show any band corresponding to phospho-Chk1 (Figure 3.32), 
indicating that the ATR/Chk1-mediated checkpoint may not be strongly engaged in these 
cells. We also looked at the phosphorylation of p53 as one of the downstream targets of 
the ATR/ATM signaling pathway. Western blot analysis showed that p53 is strongly 
phosphorylated at serine 15 in Rad21-depleted/Myc-overexpressing cells in comparison 
with a slight increase observed in Myc-overexpressing cells or Rad21-depleted cells 
(Figure 3.32). Since these cells are mainly arrested in G2/M, we hypothesized that 
activation of ATM and its downstream target, p53, is responsible for this phenotype. In 
agreement with our hypothesis, ATM inhibition by caffeine treatment decreased the 
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percentage of G2/M population of Rad21-depleted/Myc-overexpressing cells compared to 
the cells that were not treated with caffeine (Figure 3.33). In addition, the reduction in 
G2/M population was accompanied by a slight increase in the sub-G1 population, while 
the percentage of G1 and S-phase was not remarkably changed. These results propose that 
most probably ATM-mediated checkpoint was activated upon Myc activation in Rad21-
depleted cells and by causing G2 arrest may exert a protective role against mitotic 
catastrophe in these cells. 
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Figure 3.33. The effect of ATM inhibition in cell cycle profile of U2OS-
MycER cells   
Cells were transfected with siRad21 or siCtrl and simultaneously treated with 
ethanol or OHT. At 48 hours post transfection, cells were treated with caffeine (5 
mM) or PBS (as control) for additional 16 hours. Cells were then collected and 
stained with propidium iodide (PI). (A) FACS profile of PI-stained cells showing 
the cell cycle distribution of the cells at 48 hours post transfection (before 
starting the treatment) and 16 hours later after caffeine or PBS treatment. (B) The 
percentage of cells in each phase is plotted. The experiment was performed once. 
To further characterize the role of p53 in G2/M arrest observed in these cells, we depleted 
p53 in p53-proficient Bz1 R26MycER MEF cell line by stably overexpressing a potent 
shRNA targeting p53. The efficiency of p53 knock-down in these cells was assessed by 
treating cells with doxorubicin, a potent p53 inducer. Western blot analysis for the total 
p53 level showed an accumulation of the protein in doxorubicine-treated cells that stably 
overexpressed a non-targeting shRNA (shRenilla). In contrast in doxorubicin-treated cells 
stably overexpressing shp53 we did not detect any band corresponding to p53 (Figure 
3.35A), indicating the potency of p53 knock-down by shRNA.  
We then transfected shp53- and shRenilla-overexpressing cells with siRad21 or siCtrl and 
examined cell viability, cell cycle and DDR. shp53-overexpressing cells that were 
transfected with siRad21, unlike shRenilla-overexpressing cells, showed a slight increase 
in cell death upon Myc activation (Figure 3.34). However, the level of ϒH2AX 
accumulation detected upon Myc activation in Rad21-depleted cells was mostly 
unchanged between p53-silenced and control cells (Figure 3.35A and Figure 3.35B).  
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Figure 3.34. The effect of Rad21 depletion on cell death and cell growth of 
Bz1 R26-MycER MEF cell line  
Bz1 R26-MycER cell line overexpressing shp53 or shRenilla cells were reverse 
transfected with 2 different siRNAs against Rad21 (siRad21_1 and siRad21_2) 
and simultaneously were treated with OHT or ethanol. After 48 hours from 
transfection, cells were collected and counted. (A) Percentage of cell death 
measured by trypan blue staining. (B) Quantification of the number of live cells 
(initial cell number was 9×104). The experiment was performed once. 
 
 
Figure 3.35. Western blot analysis of shp53- and shRenilla-overexpressing 
Bz1 R26-MycER MEF cell line (See figure legend next page) 
A B 
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(A) Cells were transfected with siRad21 or siCtrl and treated with OHT or 
ethanol at the same time. Cells were harvested at 48 hours post transfection and 
subjected to western blot analysis. The efficiency of p53 knockdown was also 
evaluated by detecting the accumulation of stabilized p53 upon doxorubicin 
treatment (1 µM for 16 h). (B) Western blot analysis for H2AX phosphorylation 
was repeated with two different siRad21 (siRad21_1 and siRad21_2). Vinculin 
and Ponceau staining for histones are shown as loading controls.  
More interestingly, cell cycle analysis of Myc-induced shp53-overexpressing cells 
transfected with siRad21 showed a higher fraction of cells with more than 4n DNA 
content (Figure 3.36). These polyploid cells may be the source of reduced cell death that 
underwent aberrant endoreduplication. Therefore it could be interesting to monitor the 
cell death in long term after Rad21 knock-down to appreciate the cell death delay in p53-
inactivated cells.  
 
Figure 3.36. Cell cycle profile of shp3- and shRenilla-overexpressing Bz1 
R26-MycER MEF line upon Rad21 depletion and Myc activation 
A non-targeting siRNA (siCtrl) and two different siRNAs against Rad21 
(siRad21_1 and siRad21_2) were used to transfect the cells. Cells were treated 
with OHT or ethanol the same time of transfection. Forty-eight hours post 
transfection cells were harvested and stained with propidium iodide followed by 
FACS analysis. The experiment was performed once. 
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3.8.6 Depletion of other cohesin component and cohesin loader recapitulates 
Rad21-Myc synthetic lethality 
Although we focused on Rad21 subunit of the cohesin complex, it was interesting to 
know if the other cohesin components can also recapitulate Rad21-Myc synthetic lethal 
interaction and increase H2AX phosphorylation. For this reason, we examined the effect 
of depletion of the other cohesin complex Smc1, the cohesin loader Nipbl as well as Ctcf 
which was shown to interact with cohesin in some genomic sites on Bz1 R26-MycER 
MEF cell line. Silencing of Smc1, Nipbl and Ctcf significantly increased the percentage 
of ϒH2AX-positive cells in Myc-overexpressing cells compared to cells with normal 
Myc level. However the cell viability was not remarkably affected in these cells (Figure 
3.37).  
 
Figure 3.37. Viability and DDR assay of Bz1 R26-MycER cell line after 
cohesins knock-down  
Cells were transfected with siRNA against Rluc (negative control), Rad21, Smc1, 
Nipbl and Ctcf and simultaneously treated with OHT or ethanol. Forty-eight 
hours post siRNA transfection, the transfected cells were fixed and were 
subjected to DAPI and ϒH2AX immunostaining. (A) Viability ratio of Myc-
overexpressing cells (Myc-OE) to cells with normal Myc level (Myc-N) assessed 
by DAPI staining. Values are normalized to the siRluc-transfected cells. (B) 
Percentage of ϒH2AX pan-positive nuclei in transfected cells in the presence or 
absence of OHT. The assays were performed in triplicates (The data is produced 
by IIT screening unit).  
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To further characterize the impact of cohesin depletion on Myc-overexpressing cells, 
U2OS-MycER cells were transfected with siRNAs against Smc3 and Nipbl and 
simultaneously treated with OHT -to induce Myc activation- or ethanol as control. These 
cells were collected at 48 hours post transfection for RNA and protein extraction as well 
as for cell viability and cell cycle analyses.  
First, we checked the efficiency of gene knock-down by measuring the mRNA expression 
level of Smc3 and Nipbl. Real time RT-PCR showed an efficient knock-down of Smc3 
and Nipbl at the RNA level (Figure 3.38). 
 
Figure 3.38. RT-qPCR analysis of Smc3, Nipbl and Rad21 expression level 
after siRNA knock-down 
U2OS cells were transfected with the corresponding siRNA and 48 hours later 
were harvested for RNA extraction and cDNA synthesis. Relative mRNA 
expression was measured using ΔCt method, normalized with a housekeeper 
gene (RPLPO) and is plotted relative to the control (siCtrl) cells. Error bars 
indicate standard deviation. 
We also assessed the viability of the cells by trypan blue staining. Comparable to Rad21-
Myc synthetic lethality, we observed a significant reduction in the viability of cohesin-
depleted cells in the presence of elevated Myc level (Figure 3.39).  
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Figure 3.39. The effect of Smc3 and Nipbl depletion on cell death and cell 
growth of U2OS-MycER cells 
Cells were transfected with siRNAs against Smc3 and Nipbl and treated with or 
without OHT. Forty-eight hours post transfection/treatment the cells were 
collected, stained with trypan blue and counted. (A) Percentage of dead cells and 
(B) the number of live cells were plotted. The experiment was performed once. 
In addition, western blot analysis for ϒH2AX displayed a synergy between cohesin-
depletion and Myc-induced DDR (Figure 3.40).  
 
Figure 3.40. Western blot analysis for H2AX phosphorylation in U2OS-
MycER cells  
U2OS-MycER cells were transfected with siSmc3, siNipbl and siCtrl and were 
treated either with OHT or with ethanol. Cells were harvested 48 hours after 
transfection. Vinculin served as a loading control. 
Unlike the remarkable reduction of S-phase in Rad21-silenced cells, cell cycle analysis of 
Smc3- and Nipbl-depleted cells revealed just a slight reduction in the S-phase population 
(Figure 3.41). This difference could be due to the presence of residual functional protein 
after the gene knock-down. As RAD21 is the cleavable part of the cohesin, it may be 
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more feasible to achieve higher knock-down level of RAD21 compared to SMC proteins 
or NIPBL.  
 
 
Figure 3.41. FACS analysis of BrdU incorporation in U2OS-MycER cells 
transfected with siSmc3 or siNipbl  
At 48 hours post transfection and Myc activation, cells were pulsed with BrdU 
for 30 minutes, then harvested and stained with anti-BrdU antibody and 
propidium iodide. (A) FACS profiles showing the BrdU positive cells and the 
population of cells in G1 and G2/M phase of the cell cycle. (B) The percentage of 
cells in each phase of the cell cycle, as determined by BrdU staining, is plotted. 
FACS analysis was performed once. 
3.8.7 Myc is unique among other oncogenes in inducing DNA synthesis in Rad21-
depleted cells 
We observed that Rad21 silencing synergized with Myc in inducing DNA damage and 
eventually lead to synthetic lethality. To investigate whether this synergy could be 
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generalized to other oncogenes that similarly to Myc are able to induce replication stress 
and subsequently DDR, we generated a stable U2OS cell lines constitutively 
overexpressing several oncogenes such as Cyclin E1, Ras and E2F1. These oncogene-
overexpressing U2OS cell lines along with U2OS cells infected with empty vector (mock) 
were transfected with siRad21 and siCtrl and then were harvested 48 hours later for 
ϒH2AX western blot and cell cycle analyses. The analysis of DNA damage marker 
ϒH2AX in the oncogene-overexpressing cells displayed an increase of the ϒH2AX signal 
(with different extent among different oncogene-overexpressing cells) compared to mock 
cells ( 
Figure 3.42).  
 
Figure 3.42. Western blot analysis of ϒH2AX in oncogene-overexpressing 
U2OS cells  
U2OS cells stably overexpressing Cyclin E1, Ras and E2F1 along with mock 
cells were transfected with siCtrl or siRad21. U2OS-MycER cells were 
transfected with siCtrl or siRad21 and treated with OHT or ethanol at the same 
time. At 48 hours post transfection, cells were harvested and subjected to western 
blot analysis. Vinculin was used as a loading control. 
Moreover, unlike Myc-overexpressing cells, cells overexpressing oncogenes (Cyclin E1, 
Ras and E2F1) did not show further enhancement in H2AX phosphorylation when 
transfected with siRad21 (Figure 3.42). Noteworthy, no sign of massive cell death was 
seen in these oncogene-overexpressing cells up to 72 hours post siRad21 transfection 
(data not shown). 
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Notably, cell cycle analysis of oncogene-overexpressing cells (Cyclin E1, Ras and E2F1-
overexpressing U2OS cells) transfected with siRad21 revealed a reduction in S-phase 
population similar to mock transfected cells (Figure 3.43) suggesting that, in contrast to 
Myc, none of these oncogenes is capable of enforcing DNA replication and entry into S-
phase under Rad21 depleted condition.  
 
 
Figure 3.43. FACS analysis of BrdU incorporation in U2OS cells stably 
overexpressing oncogenes upon Rad21 depletion 
(A) FACS profiles depicting BrdU positive population as well as population of 
cells residing in G1 and G2/M phase. (B) Percentage of BrdU positive cells is 
plotted. FACS analysis was performed three times for MycER cells (mean values 
are shown) and once for the rest of the cells. Asterisk indicates p-value <0.01 with 
the Student t test.  
A 
B 
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3.8.8 Myc ectopic activation partially rescues the gene expression alterations 
observed in Rad21-depleted cells 
Since we observed that Myc is unique among other oncogenes in inducing DNA synthesis 
in Rad21-depleted cells, we reasoned that this effect could be at least partly due to the 
role of Myc in activating the transcription of a subset of genes involved in S-phase entry 
and progression. To investigate this possibility, we tested the expression level of several 
Myc-responsive genes including genes involved in nucleotide and ribosomal biosynthesis, 
cell cycle, DNA replication and DNA repair at 24 and 72 hours post siRNA transfection 
and OHT/ethanol treatment. RT-qPCR analysis revealed a modest reduction in the 
expression levels of most of the genes in Rad21-depleted cells, though Myc 
overexpression could partially rescue this effect and support gene expression to the levels 
seen in control Myc-overexpressing cells (Figure 3.44). These results were in line with 
the role of cohesin in regulating gene transcription and suggest a dominant role for Myc 
in inducing the transcription of at least the aforementioned subset of genes that are down-
regulated as a consequence of Rad21 depletion. 
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Figure 3.44. Heatmap of gene expression ratio for a subset of Myc-
responsive genes  
The heatmap depicts the log2 fold change expression level relative to control 
sample (siCtrl) measured by RT-qPCR. Red indicates up-regulation while green 
shows down-regulation. The RT-qPCR analysis was performed once with three 
biological replicates. 
To have a global view of gene expression profile under Rad21 depletion and Myc 
overexpression conditions, we profiled RNA expression level of transfected U2OS-
MycER cells by RNA-sequencing. To minimize the secondary effect that cell cycle 
distribution may have on global gene expression, cells were harvested 24 hours post 
siRNA transfection and Myc activation, a time point where cell cycle profiles of the 
different samples were still comparable. We then used unsupervised hierarchical 
clustering to classify the samples based on their expression profile. Consistent with the 
RT-qPCR analysis, we observed that siRad21-transfected cells that were overexpressing 
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Myc clustered with Myc-activated control cells but not with siRad21-silenced cells 
having normal Myc level (Figure 3.45A), suggesting a dominant role for Myc in 
regulating gene transcription in Rad21-depleted cells.  
 
Figure 3.45. Expression profiling of U2OS-MycER cells as measured by 
RNA-seq  
(A) Heatmap of global expression pattern of U2OS-MycER cells at 24 hours 
after siRNA transfection and Myc activation. Log2 fold change was measured in 
different experimental group compared to siCtrl-transfected cells. Red and green 
show up- and down-regulated genes respectively. (B) Hierarchical clustering of 
differentially expressed genes. Red in the heatmap denotes up-regulation while 
blue denotes down-regulation. The statistical significance of the expression level 
of each gene cluster was depicted in a flat heatmap on the left. In this heatmap, 
blue corresponds to statistical significant clusters while red means insignificant 
change. RNA-Seq analysis was performed once with two biological replicates. 
Next, the differentially expressed genes were classified based on the expression profile 
(Figure 3.45B) and then were annotated based on the biological processes by DAVID 
A A 
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annotation tool. Using hierarchical clustering we identified five different gene clusters as 
following: 
1. Cluster 1 that composed of genes that were down-regulated in Myc-overexpressing 
siCtrl- and siRad21-transfected cells but did not show a significant alteration in Rad21-
depleted cells. This cluster mainly consisted of genes encoding cell adhesion molecules as 
well as several developmental factors. This observation is in agreement with the role of 
Myc in repressing genes involved in cell differentiation and cell adhesion (Kleine-
Kohlbrecher et al., 2006).  
2. Cluster 2 contained genes that were down-regulated to a same extent in siRad21-
transfected cells in the presence or absence of high level of Myc, whereas Myc-activated 
control cells displayed no or slight change. This cluster was enriched in genes related to 
regulation of cell proliferation such as FGFR and TGFB2, and may argue, at least partly, 
the reason of slow-growing feature of cells depleted of Rad21. 
3. Cluster 3 acted in a similar way as cluster 1 and was composed of a group of genes that 
were up-regulated in Myc-overexpressing cells (regardless of Rad21 knock-down) while 
was mainly unchanged or slightly down-regulated in Rad21-silenced cells. This group 
consisted of genes involved in ion transport such as potassium and sodium ion transport 
genes. Apart from the role in maintaining cellular homeostasis through regulation of 
bioelectrical charges, recently several investigations have addressed the role of ion 
transport factors in cellular proliferation and in particular their role in cancer development 
and progression (Blackiston et al., 2009). Therefore, it would be interesting to 
characterize the role of this cluster of genes in Myc-induced cellular proliferation.  
3. In cluster 4, the genes were up-regulated in siRad21-transfected cells and were down-
regulated in Myc-activated cells, however transcription was not largely affected (or may 
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be compensated) in Myc-activated Rad21-depleted cells. This group contained several 
genes that were associated with cell motility, migration and adhesion.  
4. Lastly, genes in cluster 5 displayed significant up-regulation mostly in Myc-
overexpressing Rad21-silenced cells compared to Myc-overexpressing or Rad21-depleted 
cells. The genes in this cluster revealed to be linked to cell death and apoptosis and 
composed of pro-apoptotic and anti-apoptotic genes as well as several DNA-damage 
associated genes. 
We also compared the expression ratio obtained from RNA-seq analysis with RT-qPCR 
results (performed at 24 hours post siRNA transfection and Myc activation). The 
computed correlation coefficient (r) displayed a strong linear correlation between RNA-
seq and RT-qPCR analyses in OHT-treated cells transfected with siCtrl or siRad21. For 
siRad21-transfected cells, although the r value was not high, there was still a positive 
correlation between two analyses (Figure 3.46). Noteworthy, the log2 fold change was 
not similar between two methods, with RT-qPCR displaying higher values rather than 
RNA-seq. This may be the reason that RNA-seq analysis did not call any of the examined 
genes in RT-qPCR as differentially deregulated genes.    
 
 
Figure 3.46. Correlation of gene expression ratio between RNA-seq and 
RT-qPCR analyses 
Log2 fold change from RNA-seq analysis (Y axis) is plotted against log2 fold 
change determined by RT-qPCR (X axis). Correlation coefficiency (r) is shown 
in the plots 
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3.8.9 Myc-overexpression in Rad21-depleted cells increased the formation of DNA-
RNA hybrids 
Considering the dual role of Myc in prompting DNA synthesis and transcription, one 
possible source of DNA damage in Myc-overexpressing cells could be the conflict that 
may arise between DNA replication and transcription machineries. As a consequence of a 
head on collision between DNA replication apparatus and the transcription complex, a 
DNA-RNA hybrid called R-loop may be generated. If unresolved, R-loops may lead to 
DNA damage. Therefore, we sought to examine if Myc overexpression in control and 
Rad21-depleted cells increases R-loop formation. To this end, we performed genome 
wide profiling of DNA-RNA hybrids by DNA-RNA immunoprecipitation (DRIP) using a 
specific antibody that recognizes DNA-RNA hybrids. We then applied next generation 
sequencing to map the regions in the genome harboring R-loops.  
DRIP-seq analysis did not show any increase in the number of S9.6 peaks in Myc-
overexpressing cells (625), compared to control cells (756). However this number was 
slightly increased in Rad21-depleted cells (1325) and was remarkably increased in Myc-
induced Rad21-silenced cells (3580, Figure 3.47A). The majority of the peaks in Myc-
overexpressing or siRad21-transfected cells were also found in Myc-activated Rad21-
depleted cells. These cells also acquired additional S9.6 peaks (Figure 3.47B).  
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Figure 3.47. S9.6 peak number resulted from DRIP-seq analysis 
U2OS-MycER cells were transfected with siCtrl or siRad21 and treated with 
ethanol or OHT. At 48 hours post transfection, the cells were fixed and then 
lysed in a DRIP buffer. Immunoprecipitated material by S9.6 was followed by 
high-throughput sequencing. (A) Quantification of the total number of peaks. (B) 
Pair wise overlap of S9.6 peaks between different experimental conditions. S9.6 
DRIP was performed once. 
 
Moreover, the S9.6 peaks were mapped to intergenic and intragenic regions and to a less 
extent were found in promoters. This pattern was similar between different experimental 
groups (Figure 3.48).  
 
A 
B 
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Figure 3.48. Distribution of the S9.6 peaks in different genomic sites 
promoters (brown), intragenic (mustard) and intergenic (light cream). 
We also looked at the Myc-bound genes and analyzed whether the S9.6 preferentially 
enriched in those genomic sites. For this, we retrieved the Myc ChIP-seq datasets on 
U2OS cells that overexpress Myc in a doxycycline-inducible manner (treatment time 30 
hr) [GEO accession GSM1231598, (Walz et al., 2014)]. Myc-bound genes were defined 
as a subset of genes having a Myc peak on the promoter (-2000,1000) in Dox-induced 
cells. We also defined Myc-target genes as those genes that are bound by Myc in both un-
induced and Dox-induced cells, but the binding intensity is increased upon Myc 
induction. By computing the fraction of gene bodies associated with Myc and overlapping 
them with the S9.6 peaks, we did not see any enrichment of S9.6 signal in Myc-bound or 
Myc-target gene bodies compared to the overall gene bodies overlapped with S9.6 peaks 
(Figure 3.49), indicating that DNA-RNA hybrids, in Myc-activated siRad21-transfected 
cells are not formed selectively on Myc target genes . 
 119 
 
 
Figure 3.49. Quantification of S9.6 enrichment in Myc-bound genes (left) 
and Myc-target genes (right) compared to its enrichment in all genes. 
 
It has been shown that early replication fragile sites (that are replicated early in the 
genome and are susceptible to fork collapse under replication stress) map to actively 
transcribed genes (Barlow et al., 2013). To see if the S9.6 signal maps to early replication 
zones, we retrieved Repli-seq datasets on human embryonic stem cells [GEO accession 
GSE51334, (Pope et al., 2014)] and associated the S9.6 peaks to early and late replication 
sites. We found S9.6 peaks both in early and late replication regions, although the signal 
tended to be preferentially associated with early replication zones. The fraction of the 
S9.6 peaks residing in early replication sites in siRad21-depleted Myc-overexpressing 
cells was slightly higher compared to other samples, indicating that although DNA-RNA 
hybrid may form preferentially in early replication sites, the frequency of R-loop 
formation is similar in both early and late replication sites (Figure 3.50).  
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Figure 3.50. Distribution of the S9.6 peaks in early (white) and late (blue) 
replication sites. 
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4 Discussion 
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Considering the role of Myc as an oncoprotein, Myc inhibition has been proposed as a 
promising strategy for the treatment of Myc-driven cancers. However, concerns are often 
raised regarding the side effects of Myc inhibition on normal cells. There are also some 
practical difficulties in designing inhibitors against Myc (Soucek et al., 2008). Recently 
the concept of “synthetic lethality” has been suggested for the development of selective 
and less toxic anticancer targets and drugs (Kaelin, 2005). For example, reminiscent to 
the synthetic lethality of ATR and Chk1 inhibition in Myc-overexpressing cancer cells, 
several clinical trials are ongoing with the Chk1-inhibitors (LY2606368 and SCH 
900776) and ATR inhibitors (AZD6738 and VX-970) in patients with variety of cancers 
(ClinicalTrials.Gov). A prerequisite of these studies is the thorough knowledge of the 
underlying pathways through which Myc can act. 
In order to identify genes involved in modulating Myc-induced replicative stress, we 
carried out a high-throughput RNAi screen, using a conditional Myc-overexpressing MEF 
cell line (MycER-MEF), across 1400 potentially druggable genes and 1200 genes with 
the potential role in genome instability. Our siRNA screen revealed a subset of “positive 
hits” including Myc-synthetic lethal genes as well as genes whose knock-down increased 
ϒH2AX, selectively in Myc-overexpressing cells. We noticed that some of the synthetic 
lethal hits also displayed higher percentage of ϒH2AX-positive cells. Without ruling out 
the possibility that H2AX phosphorylation might be a consequence of cell death, 
accumulation of cytotoxic DNA damage could also be a cause of the reduction in cell 
viability. We also identified a group of genes whose knock-down increased cell viability 
and/or reduced ϒH2AX immunofluorescence signal. Though, having low statistical 
power and low signal-to-noise ratio in this case, limited our confidence in calling the hits. 
The initial hit rate of the druggable and genome instability screens -considering only the 
high confidence positive hits were 6.8% and 7.7% respectively. Validation of the positive 
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hits from the druggable libraries in a secondary screen yielded a validation rate of 26%. 
Interestingly, we found several common hits between Myc-SL candidates reported by 
Toyoshima et al. (Toyoshima et al., 2012) and our screen hits, providing confidence in 
our screening data. Similarly to the tested libraries, validated hits were dispersed in a 
variety of pathways and biological processes, suggesting that the events cooperating with 
Myc in reducing DDR may not be confined to the DNA damage response and repair 
pathways. Indeed, we identified several hit candidates involved in RNA transcription and 
processing as well as translation, protein synthesis and degradation.  
Interestingly, in a previous study (Paulsen et al., 2009) the mRNA processing module was 
also the most significantly enriched group of genes whose knock-down induced 
significant H2AX phosphorylation. While it is conceivable that mRNA processing could 
affect gnome stability indirectly by altering protein level, recent studies pointed to a more 
direct mechanism linking some mRNA processing genes to genome maintenance. For 
example, depletion of splicing factor ASF/SF2 led to increased R-loop formation and 
generation of DNA double-strand breaks (Li and Manley, 2005). Moreover, 
pharmacological inhibition of the spliceosome was shown to impair survival and 
tumorigenesis of Myc-dependent breast cancers in vivo (Hsu et al., 2015). It has also been 
demonstrated that several RNA processing factors such as SRSF1 and the core snRNP 
assembly genes are direct targets of Myc and are necessary for Myc oncogenic activity 
(Das et al., 2012, Koh et al., 2015). Taken together, these data indicate the important role 
of mRNA processing machinery and splicing factors in Myc-overexpressing cells.  
In line with the previous data, we found a number of splicing factors such as 
Serine/Arginine-Rich Splicing Factor 3 (SRSF3), Splicing Factor 3a (SF3A3) and several 
subunits of Splicing Factor 3b (SF3b) among SL and/or DDR-up hits. The core 
spliceosomal factor SF3B1 (together with BUD31 and U2AF1) was also shown by 
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another group recently as a synthetic lethal gene in Myc-overexpressing cells (Hsu et al., 
2015). In addition, we validated the Myc-synthetic lethal interaction with SRSF3 
depletion in human osteosarcoma U2OS-MycER cells and showed that this synthetic 
lethality was accompanied with accumulation of ϒH2AX. Thus, while it has been 
proposed that Myc transcription factor via its ability to increase the synthesis of precursor 
mRNAs, relies heavily on effective mRNA processing, it would be interesting to 
understand how the disruption in mRNA splicing synergized with Myc in inducing DDR. 
In this regard, one may assume that disrupted mRNA splicing by increasing R-loop 
formation may generate replication fork barrier and boost Myc-induced replicative stress. 
In addition, we and the others have observed an increased expression of splicing factors 
(such as SRSF3 in current study and SRSF1 in Das et al. study) upon Myc activation, 
whether this can be generalized to other splicing factors or whether Myc overexpression 
engages specific splicing factors for efficient proliferation remains to be determined. 
Also, the consequences of altered mRNA expression level as well as new alternative 
splicing events upon depletion of splicing factors in the context of Myc overexpression 
may be an interesting issue to be addressed.  
In addition to mRNA processing factors, our siRNA screen also identified a number of 
candidates involved in mRNA transcription. Of particular interest, we found Cyclin 
dependent kinase 12 (CDK12) among DDR-up hits. CDK12 was previously linked to 
DNA damage response (Blazek et al., 2011) and was also identified as a Myc-synthetic 
lethal candidate (Toyoshima et al., 2012). CDK12 has been demonstrated to interact with 
CCNK (Cyclin K) to phosphorylate the RNA polymerase II C-terminal domain (CTD), 
thus positively regulating gene expression. Different studies have shown that depletion of 
CdK12/Cyclin K resulted in decreased expression of long genes with high number of 
exons including DDR genes such as ATR, BRCA1, FANCI and FANCD2 and in this way 
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sensitized cells to a variety of DNA damage agents (Blazek et al., 2011, Liang et al., 
2015).  
Validating the preliminary result from screen in U2OS-MycER cells, we demonstrated 
that Myc activation resulted in synergistic accumulation of ϒH2AX in cells depleted of 
either Cdk12 or Cdk13 (Cdk12 paralog) or Cyclin K. We also observed a significant 
reduction in the viability of Myc-overexpressing cells once CDK12, Cdk13 or Cyclin K 
(but not Cdk12) was silenced. We reasoned that the effect of accumulation of ϒH2AX on 
cell viability and survival of Myc-activated cells depleted of Cdk12 might be more 
evident at later time points. However, inconsistent with the previous studies, we could not 
detect any change in the expression of the examined DDR genes (ATR, ATM and 
FANCD2) upon Cdk12 and Cyclin K depletion, therefore it would be of merit to analyze 
the global expression profiles upon Cdk12 and Cyclin K gene knock-down. Of note, since 
it was shown that each of these proteins, besides some common genes, controls the 
expression of distinct subset of genes, dissecting gene expression profiles of Cdk12-, 
Cdk13- and Cyclin K-depleted cells, would be informative to understand how these 
proteins are linked to DNA damage response and whether or not these proteins, at least in 
their transcriptional role, are functionally redundant. As it was previously shown that 
CDK12 and CDK13 have positive effects on gene transcription (Liang et al., 2015, 
Blazek et al., 2011), it would be interesting to know if and how Myc overexpression 
affects the expression of down-regulated genes in the cells depleted of Cdk12 or Cdk13 or 
Cyclin K. 
CDK12 and CDK13 seem to also interact with mRNA processing factor through their N-
terminal serine-arginine dipeptide-rich regions (Liang et al., 2015, Berro et al., 2008). 
Indeed, not only many splicing factors including some of our aforementioned hits were 
co-purified with Cdk12 and Cdk13, also Cdk12 and Cdk13 knock-down affected the 
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expression of genes involved in RNA processing (Liang et al., 2015). Therefore, it may 
be intriguing to investigate the functional link between Cdk12/Cdk13 and splicing factors 
particularly in the context of Myc hyper-activation. 
In the second part of our study, we sought to better understand the molecular mechanism 
underlying the synthetic lethal interaction between Myc and Rad21 (a component of the 
cohesin complex). Rad21 was among the Myc-synthetic lethal candidates in Toyoshima 
et al. study (Toyoshima et al., 2012) and, due to the robust effect, was selected to serve as 
a positive SL/DDR-up control in our RNAi screen. Further validation by us, revealed that 
Rad21 depletion in different Myc overexpressing cell types (MEF-, U2OS- and NMuMG-
MycER cells) caused a massive cell death, demonstrating that the synthetic lethality is not 
cell type specific. Moreover, Rad21 silencing caused a remarkable increase in ϒH2AX 
level selectively in Myc-activated cells, suggesting that the synthetic lethality is 
subsequent to the accumulation of cytotoxic DNA damage. Moreover, Rad21-depleted 
cells with endogenous level of Myc were viable and did not exhibit accumulation of 
ϒH2AX. These results support the idea that DNA damage response in Myc activated cells 
depleted of Rad21 is unlikely to be due to the lack of chromosomal cohesion and 
missegregation of the sister chromatids. In line with this notion, cohesin-depleted cells or 
cells that are heterozygous for NIPBL (a cohesin loader) showed normal mitosis (Liu et 
al., 2009), implying that even very low levels of cohesin may be sufficient for proper and 
functional sister chromatid cohesion. An alternative (yet not mutually exclusive) 
explanation is that other mechanisms such as DNA catenations can act redundantly with 
the cohesin complex to provide a cohesive force during mitosis (Díaz-Martínez et al., 
2007).  
Cohesins have also been shown to facilitate repair of double strand breaks by homologous 
recombination (Wu and Yu, 2012). However, in contrast to the previous data, we did not 
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see any further sensitivity in U2OS cells to DNA damaging agents when Rad21 was 
depleted. In addition, we observed that irradiated U2OS cells, after one day recovery, 
were able to efficiently repair DNA damage, as was shown by ϒH2AX reduction. This 
discrepancy may be due to the difference in irradiation dose and to the preferred DNA 
repair pathway cells may choose under certain circumstances. While ϒH2AX was 
suggested by several studies as a valid measure of DNA repair (Rothkamm et al., 2003), 
examining the other DNA repair markers involved in homologous-directed repair and 
non-homologous end joining repair such as RAD51, 53BP1 and BRCA1 would give us 
better understandings on the efficiency of DNA repair in Rad21-depleted cells in face of 
DNA damage. 
Recently the role of RAD21 as a part of cohesion complex is expanding far more than just 
involving in sister chromatid cohesion and DNA repair. Recent findings showed not only 
an enrichment of cohesin at replication origins, but also a physical interaction between 
cohesin and pre-replication complex (Guillou et al., 2010). In line with these data, we 
detected RAD21 protein enriched on newly synthesized DNA by iPOND technique. 
Although the “cohesin barrier” model suggests that cohesins deposited before DNA 
replication are stable and block subsequent fork progression, our data support the notion 
that cohesins are highly dynamic and transiently chromatin-associated complexes before 
S-phase (Gerlich et al., 2006). Moreover, evidence of cohesin interactions with fork 
stability factors such as PCNA, argues that functional cohesin loading probably takes 
place during DNA replication and may be coordinated with fork progression. In this way 
cohesins may be deposited at higher levels on both sister chromatids (on leading and 
lagging strands) during replication. After fork passage, as a result of the activity of 
ESCO1/2 acetyltransferase, the cohesin complex may be converted to a state competent 
for sister pairing. 
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This data together with the results of DNA combing analysis that displayed a remarkable 
increase in unidirectional replication fork in Rad21-depleted cells, may explain the 
essential role of the cohesin complex in fork stability and progression. Unexpectedly, 
DNA combing analysis also showed higher fork speed in Rad21-depleted cells compared 
to control cells. This data seem difficult to reconcile with the high frequency of 
unidirectional replication forks in Rad21-depleted cells. One possible reason to account 
for the higher fork speed in these cells could be the size of the chromatin loops under 
cohesin-depleted condition. 
We also found that Myc is able to partially rescue DNA synthesis in Rad21-depleted 
cells, however, replication reinforcement imposed by Myc overexpression results in a 
replicative stress over time. How Myc is able to restore DNA replication in Rad21-
depleted cells? One explanation could be that Myc hyper-activation leads to unscheduled 
origin firing, however, in the absence of RAD21, DNA replication cannot proceed long 
enough, resulting in replication fork stalling and collapse. Although our results on DNA 
combing do not favor the effect of Myc on origin activation, it has been shown by several 
studies that Myc overexpression boosts origin firing (Dominguez-Sola et al., 2007, 
Srinivasan et al., 2013). It should also be noted that due to the high percentage of 
unidirectional forks which were not taken into account in the DNA combing analysis 
(particularly in siRad21-transfected cells), the measured inter-origin distances may be 
biased toward the tracks with symmetric labeling and not be reflective of the real 
situation. More precise techniques, such as Repli-seq, may be required to clarify the 
replication profile of the cells in this case.  
We propose that as a result of the progressive accumulation of DNA damage in S-phase 
and activation of G2 checkpoint, at least through phosphorylation of p53, Myc-activated 
cells depleted of Rad21 get arrested in G2/M phase to avoid mitotic catastrophe. In an 
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effort to relieve the G2 checkpoint in these cells, we saw that ATM inhibition led to 
increased cell death while p53 knock-down, without affecting cell viability, enhanced the 
percentage of the polyploid population. This controversy may stem from the difference 
between inhibiting ATM -that acts upstream of p53 in the DDR pathway- and knocking-
down p53 that acts at the downstream of the cascade. In line with our observation, it has 
been shown that irradiated p53-mutated cells before undergoing cell death, entered 
aberrant endoreduplication resulting in the formation of polyploid cells (Illidge et al., 
2000). Therefore, it would be interesting to see whether Myc synthetic lethality with 
Rad21, though with a delay, can occur also in the absence of functional p53. 
Comparing Myc with the other oncogenes, that similarly to Myc induces replication 
stress, we found that Myc is unique in enforcing DNA synthesis and triggering DDR in 
Rad21-silenced cells. As a result, we think that the combination of transcriptional and 
non-transcriptional roles of Myc is important for the observed effect of Myc on DNA 
replication in Rad21-depleted cells. RNA expression analysis in Rad21-depleted cells 
show several deregulated genes, including genes involved in cell cycle progression and 
DNA replication, however Myc overexpression in these cells was able to partially re-
establish gene expression profile toward the expression profile of Myc activated cells. 
This result also exclude the possibility that the Myc-induced replication stress in Rad21-
silenced cells might be due to the deregulation of Myc target genes necessary for DNA 
synthesis.   
The dominant effect of Myc in provoking gene transcription in Rad21-depleted cells, also 
led us think that the increased DDR in these cells may originate from the dual role of Myc 
in inducing DNA replication and in directing RNA transcription. Supporting this idea, 
DRIP-seq analysis on Rad21-depleted cells upon Myc overexpression, revealed a 
remarkable increase in the DNA-RNA hybrids, as an indication of R-loop formation. 
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Although we did not find any preferential enrichment of R-loops in the vicinity of Myc-
bound genes, we cannot rule out the R-loops generated as a result of Myc-induced 
replication. This became more interesting as we saw R-loops preferentially occurring in 
early replication sites. Therefore, more thorough analyses of replication dynamics as well 
as Myc-mediated transcription are needed to dissect the impact of Myc overexpression on 
R-loop formation in Rad21-depleted cells.   
Recently Yan et al. showed the presence of dense clusters of different transcription 
factors (TF) in the genome that are exclusively formed around the cohesin complex and 
act as a memory for TF establishing. These transcriptional dense clusters were shown to 
localize close to the transcription sites and interestingly Myc is almost exclusively present 
in such clusters (Yan et al., 2013). Given the fact that replication origins are shown to 
preferentially locate close to transcription start site, one may assume that by Rad21 
depletion, the TF dense clusters might be disassembled and this may result in a disruption 
of the coordination of transcription and DNA replication in these sites. Further studies are 
needed to investigate the impact of the cohesins depletion on such TF clusters and their 
neighboring genomic regions.   
Taken together, our data highlights the pleiotropic roles of Rad21 in particular (and the 
cohesin complex in general) in different cellular processes such as cohesion, DNA 
replication and gene transcription. In addition, we showed that Myc overexpression by 
counteracting the effect of Rad21 depletion on DNA replication and transcription, 
imposes a severe replicative stress in cells and eventually leads to cell death.  
In summary, by means of a high-throughput siRNA screen, we identified several genes 
that are required to ensure genome stability in Myc-overexpressing cells, followed by 
validation of the selected hits. Prospective studies will elucidate how targeting these 
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molecules can influence the malignant phenotypes of cancer cells with deregulated Myc 
in vitro and in vivo, and may ultimately used for therapeutic intervention. 
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